EP1522277A2 - Graft material attachment device and method - Google Patents

Graft material attachment device and method Download PDF

Info

Publication number
EP1522277A2
EP1522277A2 EP04256158A EP04256158A EP1522277A2 EP 1522277 A2 EP1522277 A2 EP 1522277A2 EP 04256158 A EP04256158 A EP 04256158A EP 04256158 A EP04256158 A EP 04256158A EP 1522277 A2 EP1522277 A2 EP 1522277A2
Authority
EP
European Patent Office
Prior art keywords
stent
graft
attachment device
graft material
biocompatible
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP04256158A
Other languages
German (de)
French (fr)
Other versions
EP1522277B1 (en
EP1522277A3 (en
Inventor
Juan Borges
Clifford J. Dwyer
William L. Howat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cordis Corp
Original Assignee
Cordis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cordis Corp filed Critical Cordis Corp
Publication of EP1522277A2 publication Critical patent/EP1522277A2/en
Publication of EP1522277A3 publication Critical patent/EP1522277A3/en
Application granted granted Critical
Publication of EP1522277B1 publication Critical patent/EP1522277B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • A61F2/07Stent-grafts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95Instruments specially adapted for placement or removal of stents or stent-grafts
    • A61F2/9522Means for mounting a stent or stent-graft onto or into a placement instrument
    • A61F2/9526Means for mounting a stent or stent-graft onto or into a placement instrument using a mandrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/89Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure the wire-like elements comprising two or more adjacent rings flexibly connected by separate members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95Instruments specially adapted for placement or removal of stents or stent-grafts
    • A61F2/9522Means for mounting a stent or stent-graft onto or into a placement instrument
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • A61F2/07Stent-grafts
    • A61F2002/075Stent-grafts the stent being loosely attached to the graft material, e.g. by stitching
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2002/828Means for connecting a plurality of stents allowing flexibility of the whole structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0039Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in diameter

Definitions

  • the present invention relates to devices and methods for repairing aneurysms and more particularly, to percutaneously and/or intraluminally delivered devices and methods for repairing aneurysms such as abdominal aortic aneurysms and thoracic aortic aneurysms.
  • the present invention also relates to devices utilized to attach graft material to stents or other substrates for fabricating devices for repairing aneurysms and the like.
  • An aneurysm is an abnormal dilation of a layer or layers of an arterial wall, usually caused by a systemic collagen synthetic or structural defect.
  • An abdominal aortic aneurysm is an aneurysm in the abdominal portion of the aorta, usually located in or near one or both of the two iliac arteries or near the renal arteries. The aneurysm often arises in the infrarenal portion of the diseased aorta, for example, below the kidneys.
  • a thoracic aortic aneurysm is an aneurysm in the thoracic portion of the aorta. When left untreated, the aneurysm may rupture, usually causing rapid fatal hemorrhaging.
  • Aneurysms may be classified or typed by their position as well as by the number of aneurysms in a cluster. Typically, abdominal aortic aneurysms may be classified into five types.
  • a Type I aneurysm is a single dilation located between the renal arteries and the iliac arteries. Typically, in a Type I aneurysm, the aorta is healthy between the renal arteries and the aneurysm and between the aneurysm and the iliac arteries.
  • a Type II A aneurysm is a single dilation located between the renal arteries and the iliac arteries.
  • the aorta is healthy between the renal arteries and the aneurysm, but not healthy between the aneurysm and the iliac arteries.
  • the dilation extends to the aortic bifurcation.
  • a Type II B aneurysm comprises three dilations. One dilation is located between the renal arteries and the iliac arteries.
  • the aorta is healthy between the aneurysm and the renal arteries, but not healthy between the aneurysm and the iliac arteries.
  • the other two dilations are located in the iliac arteries between the aortic bifurcation and the bifurcations between the external iliacs and the internal iliacs.
  • the iliac arteries are healthy between the iliac bifurcation and the aneurysms.
  • a Type II C aneurysm also comprises three dilations. However, in a Type II C aneurysm, the dilations in the iliac arteries extend to the iliac bifurcation.
  • a Type III aneurysm is a single dilation located between the renal arteries and the iliac arteries.
  • the aorta is not healthy between the renal arteries and the aneurysm. In other words, the dilation extends to the renal arteries.
  • a ruptured abdominal aortic aneurysm is presently the thirteenth leading cause of death in the United States.
  • the routine management of abdominal aortic aneurysms has been surgical bypass, with the placement of a graft in the involved or dilated segment.
  • resection with a synthetic graft via transperitoneal or retroperitoneal procedure has been the standard treatment, it is associated with significant risk.
  • complications include perioperative myocardial ischemia, renal failure, erectile impotence, intestinal ischemia, infection, lower limb ischemia, spinal cord injury with paralysis, aorta-enteric fistula, and death.
  • Surgical treatment of abdominal aortic aneurysms is associated with an overall mortality rate of five percent in asymptomatic patients, sixteen to nineteen percent in symptomatic patients, and is as high as fifty percent in patients with ruptured abdominal aortic aneurysms.
  • Disadvantages associated with conventional surgery include an extended recovery period associated with the large surgical incision and the opening of the abdominal cavity, difficulties in suturing the graft to the aorta, the loss of the existing thrombosis to support and reinforce the graft, the unsuitability of the surgery for many patients having abdominal aortic aneurysms, and the problems associated with performing the surgery on an emergency basis after the aneurysm has ruptured.
  • the typical recovery period is from one to two weeks in the hospital and a convalescence period, at home, ranging from two to three months or more, if complications ensue. Since many patients having abdominal aortic aneurysms have other chronic illnesses, such as heart, lung, liver and/or kidney disease, coupled with the fact that many of these patients are older, they are less than ideal candidates for surgery.
  • aneurysms The occurrence of aneurysms is not confined to the abdominal region. While abdominal aortic aneurysms are generally the most common, aneurysms in other regions of the aorta or one of its branches are possible. For example, aneurysms may occur in the thoracic aorta. As is the case with abdominal aortic aneurysms, the widely accepted approach to treating an aneurysm in the thoracic aorta is surgical repair, involving replacing the aneurysmal segment with a prosthetic device. This surgery, as described above, is a major undertaking, with associated high risks and with significant mortality and morbidity.
  • Stent-grafts or endoprostheses are now Food and Drug Administration (FDA) approved and commercially available.
  • FDA Food and Drug Administration
  • Their delivery procedure typically involves advanced angiographic techniques performed through vascular accesses gained via surgical cutdown of a remote artery, which may include the common femoral or brachial arteries.
  • a remote artery which may include the common femoral or brachial arteries.
  • the appropriate size introducer Over a guidewire, the appropriate size introducer will be placed. The catheter and guidewire are passed through the aneurysm. Through the introducer, the stent-graft will be advanced to the appropriate position.
  • Typical deployment of the stent-graft device requires withdrawal of an outer sheath while maintaining the position of the stent-graft with an inner-stabilizing device.
  • stent-grafts are self-expanding; however, an additional angioplasty procedure, e.g., balloon angioplasty, may be required to secure the position of the stent-graft. Following the placement of the stent-graft, standard angiographic views may be obtained.
  • additional angioplasty procedure e.g., balloon angioplasty
  • arteriotomy closure typically requires open surgical repair.
  • Some procedures may require additional surgical techniques, such as hypogastric artery embolization, vessel ligation, or surgical bypass in order to adequately treat the aneurysm or to maintain blood flow to both lower extremities.
  • additional surgical techniques such as hypogastric artery embolization, vessel ligation, or surgical bypass in order to adequately treat the aneurysm or to maintain blood flow to both lower extremities.
  • additional advanced catheter directed techniques such as angioplasty, stent placement and embolization, in order to successfully exclude the aneurysm and efficiently manage leaks.
  • endoprostheses represent a significant improvement over conventional surgical techniques
  • One concern with the use of endoprostheses is the prevention of endo-leaks and the disruption of the normal fluid dynamics of the vasculature.
  • Devices using any technology should preferably be simple to position and reposition as necessary, should preferably provide an acute, fluid tight seal, and should preferably be anchored to prevent migration without interfering with normal blood flow in both the aneurysmal vessel as well as branching vessels.
  • devices using the technology should preferably be able to be anchored, sealed, and maintained in bifurcated vessels, tortuous vessels, highly angulated vessels, partially diseased vessels, calcified vessels, odd shaped vessels, short vessels, and long vessels.
  • the endoprostheses should preferably be highly durable, extendable and re-configurable while maintaining acute and long-term fluid tight seals and anchoring positions.
  • the endoprostheses should also preferably be able to be delivered percutaneously utilizing catheters, guidewires and other devices which substantially eliminate the need for open surgical intervention. Accordingly, the diameter of the endoprostheses in the catheter is an important factor. This is especially true for aneurysms in the larger vessels, such as the thoracic aorta.
  • the present invention overcomes the potential disadvantages associated with percutaneously delivered endoprostheses as briefly described above.
  • the present invention is directed to an attachment device.
  • the attachment device comprises a deformable, partially tubular band having a slotted opening for accepting a portion of a first substantially flexible element and a portion of a second substrate element.
  • the present invention is directed to a stent graft.
  • the stent graft comprises one or more stent structures, a biocompatible graft material affixed to the one or more stent structures, and at least one attachment device for securing the biocompatible graft material to the one or more stent structures.
  • the at least one attachment device comprising a deformable, partially tubular band having a slotted opening for accepting a portion of the one or more stent structures and a portion of the biocompatible graft material.
  • the present invention is directed to a method for attaching graft material to a stent structure.
  • the method comprises positioning graft material around a stent structure, positioning at least one attachment device such that the graft material is sandwiched between the at least one attachment device and a portion of the stent structure, and crimping the at least one attachment device around the graft material at the portion of the stent structure.
  • the abrasion resistant stent-graft of the present invention comprises at least one stent segment and a highly durable, abrasion-resistant graft material attached thereto.
  • the graft material may be attached to the at least one stent segment in any number of ways.
  • the stent-graft may be utilized as a component of a larger system, for example, in a system for repairing abdominal aortic aneurysms, or as a stand-alone device. In either embodiment, the stent-graft is utilized as a fluid carrying conduit that is preferably percutaneously delivered, but may also be utilized surgically.
  • the at least one stent segment may comprise any suitable scaffold structure and may be fabricated from any number of biocompatible materials.
  • the at least one stent segment may be self-expanding or balloon expandable.
  • the abrasion resistant stent-graft of the present invention is preferably percutaneously delivered, and as such it is preferably designed with the smallest diameter possible. In order to achieve the smallest diameter possible, thinner graft materials are needed. However, stent-grafts are typically positioned within the body in vessels that have relatively high hydrodynamic forces, thus requiring graft materials which are able to withstand these forces. Essentially, these forces tend to wear the graft material at the points where it is connected to the at least one stent segment. Over time, the graft material may develop microleaks which obviously defeat the purpose of the stent-graft, namely, as a by-pass conduit.
  • the abrasion resistant stent-graft of the present invention utilizes a biocompatible, high tensile strength, abrasion resistant, highly durable yarn which may be woven, knitted or braided into a graft material without sacrificing diameter.
  • the yarn or thread may comprise a single component or it may be blended with one or more other suitable materials to achieve various desirable characteristics, including abrasion resistance, flexibility and thinness.
  • One such yarn comprises ultra high molecular weight polyethylene, which is commercially available.
  • the abrasion resistant stent-graft of the present invention is a highly durable stent-graft which, because of its thin graft material, may be percutaneously delivered more easily than present stent-grafts.
  • the attachment device of the present invention comprises a clip or band structure that may be utilized to attach graft material to a stent thereby forming a covered stent, stent-graft, endoleg, endoprosthesis or any other device that requires a covering to be attached to a substrate.
  • the attachment device may be fitted over the graft material and a segment of the stent, such as a stent strut, and then deformed to create a snug fit around the stent segment with the graft material sandwiched therebetween.
  • a device similar to pliers, may be utilized to deform or crimp the attachment device to the stent segment.
  • the attachment device of the present invention may be utilized to secure or attach graft material to a stent or stent like structure without the need for sutures or staples as is currently utilized. Alternately, the attachment device of the present invention may be utilized in combination with other securing means such as staples or sutures.
  • the attachment device of the present invention offers a number of advantages over existing attachment technology.
  • the attachment device does not make direct contact with the stent because the graft material is sandwiched therebetween. If the attachment device were constructed from a metallic material different from the metallic material comprising the stent, and if the two components were in direct contact, there may be corrosion due to galvanic action.
  • the attachment device does not require a breach of the graft material. Accordingly, there is less likely of a chance of leakage and graft failure due to tearing.
  • the attachment device is positioned on the surface of the stent-graft that is in contact with the vessel wall; therefore, in the unlikely even the attachment device becomes dislodged, it will be trapped between the vessel wall and the stent-graft and pose substantially no threat of creating a particle emboli.
  • the attachment device may serve a dual role. If needed, the attachment device may be fabricated from a highly radiopaque material and function as a marker band for proper placement of the stent-graft.
  • the attachment device of the present invention is simple and inexpensive to manufacture.
  • the attachment device is also simple to utilize.
  • the present invention is directed to an endovascular graft which may be utilized as a component in a system for use in treating or repairing aneurysms.
  • Systems for treating or repairing aneurysms such as abdominal aortic aneurysms and thoracic aortic aneurysms come in many forms.
  • a typical system includes an anchoring and/or sealing component which is positioned in healthy tissue above the aneurysm and one or more grafts which are in fluid communication with the anchoring and/or sealing component and extend through the aneurysm and anchor in healthy tissue below the aneurysm.
  • the grafts are the components of the system that are utilized to establish a fluid flow path from one section of an artery to another section of the same or different artery, thereby bypassing the diseased portion of the artery.
  • Current systems are preferably percutaneously delivered and deployed.
  • the present invention is directed to one component of an aneurysm repair system; namely, the endovascular graft of stent-graft. Accordingly, the following detailed description is directed to the endovascular graft.
  • the endovascular graft comprises at least one stent segment and a highly durable, abrasion-resistant graft material attached thereto.
  • the endovascular graft of the present invention is supported internally by one or more individual stents, which are themselves connected to the graft in a manner which secures their position, for example, by sutures.
  • the graft of the present invention may incorporate any number of suitable stent designs, including self-expanding stents and balloon expandable stents.
  • the endovascular graft may comprise a device formed solely from the graft material.
  • FIG. 1 illustrates an exemplary embodiment of an endovascular graft 10 in accordance with the present invention.
  • the exemplary endovascular graft 10 comprises one or more first stent segments 100, one second stent segment 200 and a third stent segment 300.
  • the endovascular graft is illustrated in the figure as though the graft material were transparent.
  • the third stent segment 300 would be anchored in healthy tissue below the aneurysm and the uppermost first stent segment 100 would be in fluid communication with an anchoring and/or sealing component as briefly described above. It is important to note, however, that depending on the design of the system, an anchoring and/or sealing component may not be necessary.
  • the second stent segment 200 comprises a tapered profile, having a diameter at one end equal to that of the first stent segments 100 and a diameter at the other end equal to that of the third stent segment 300.
  • the length of the endovascular graft may be varied by the number of first stent segments 100 utilized.
  • FIG 2 is a detailed perspective view of an exemplary embodiment of the third stent segment 300.
  • the third stent segment 300 comprises a plurality of struts 302 connected in a substantially zigzag pattern.
  • the exemplary third stent segment 300 comprises three sets of zigzag-connected stents 302, thereby forming substantially diamond-shaped cells.
  • the non- connected apex 304 of each diamond shaped cell illustrated in greater detail in Figure 2A, comprises a smooth, uniform width curved region formed at the intersection of two stents 302 of each diamond-shaped cell. This shape is cut directly into the stent segment 300 during the initial machining steps, typically laser cutting, as is explained in detail subsequently, and is maintained during all subsequent finishing processing.
  • junctions 306 between the zigzag- connected stents 302, illustrated in greater detail in Figure 2B occurs at the intersection of four struts 302.
  • each junction 306 of four struts 302 comprises two indentations 308 and 310 as illustrated in Figure 2B.
  • the regions proximate the non-connected apexes 304 and the junctions 306 are generally the highest stress regions in the third stent segment 300. To minimize the stresses in these regions, these regions are designed to maintain uniform beam widths proximate where the struts 302 interconnect. Beam width refers to the width of a strut 306. Indentations 308 and 310 are cut or machined into the junctions 306 to maintain a uniform beam width in this area, which is generally subject to the highest stress.
  • junctions 306 By designing the junctions 306 to maintain uniform beam widths, the stress and strain that would normally build up in a concentrated area, proximate the junction 306, is allowed to spread out into the connecting regions, thereby lowering the peak values of the stress and strain in the stent structure.
  • the struts 302 may have a tapering width.
  • the struts 302 may be designed to become wider as it approaches a junction 306.
  • Figure 2C is an enlarged partial view of the third sent segment 300 in its expanded conditions which illustrates the tapering width of the struts 302.
  • the strut 302 proximate the junction 306 is about 0.025 cm and gradually tapers to a dimension of about 0.0178 cm in the mid-region of the strut 302 (width b).
  • the stresses in the struts 302 adjacent the junction 306 is spread out away from the junction 306.
  • the tapering of the struts 302 is accomplished during the machining of the tube of material from which the stent 300 is cut, as described in detail subsequently.
  • the stent segment 300 becomes somewhat less resistant to localized deformations, caused for example, by a protrusion within the vessel lumen.
  • This localized deformation may lead to a local torsional loading on some of the struts 302, and, therefore, since the struts 302 in this exemplary embodiment have a relatively significant portion of their length with a reduced width, their torsional rigidity is reduced.
  • the struts 302 may be maintained at a uniform width, or more preferably have a reverse taper, as illustrated in Figure 2D, wherein the width at point a is less than the width at point b.
  • the reverse taper struts 302 are about 0.025 cm proximate the junction 306 and about 0.028 cm in the central region of the struts. While this reverse taper tends to increase the stresses somewhat proximate the junctions 306, this increase is very small relative to the decrease in stresses gained by having the side indentations 308, 310 illustrated in Figure 2B, as well as the uniform width connections illustrated in Figure 2A.
  • the stent structure resists local deformation and tends to maintain a substantially circular cross-sectional geometry, even if the lumen into which the stent is positioned in non-circular in cross-section.
  • the third stent segment 300 is fabricated from a laser cut tube, as described in detail subsequently, of initial dimensions 0.229 cm inside diameter by 0.318 cm outside diameter.
  • the struts 302 are preferably 0.0229 cm wide adjacent the four strut junctions 306 and six mm long, with a reverse taper strut width.
  • the third stent segment 300 have an expanded diameter of sixteen mm.
  • the proximal portion of the graft material forming the legs is flared, having a diameter of sixteen mm.
  • This single diameter for the third stent segment of the graft system would enable its use in arteries having a non-aneurysmal region of a diameter from between eight and fourteen mm in diameter. It is also contemplated that multiple diameter combinations of third stent segment 300 and graft flare would be desirable.
  • the one or more first stent segments 100 are also formed from a shape set laser cut tube, similar to the third stent segment 300 described above.
  • the one or more first stent segments 100 comprise a single circumferential row of zigzag or sinusoidally arranged elements.
  • the first stent segment 100 comprises ten zigzag or sinusoidal undulations.
  • the one or more first stent segments 100 are formed with uniform width connections at the intersections 104 of the struts 102 forming the zigzag or sinusoidal pattern.
  • the one or more first stent segments 100 are preferably cut from tubing having an inside diameter of 0.251 cm and an outside diameter of 0.317 cm.
  • the strut widths are preferably about 0.33 cm wide adjacent strut intersections 104 and the struts 102 are preferably seven mm long and the one or more first stent segments 100 are preferably eleven mm in diameter when expanded.
  • the second stent segment 200 comprises a tapered profile, having a diameter at one end which is the same as the one or more first stent segments 100, and a diameter at the other end matching the diameter of the third stent segment 300.
  • the second stent segment 200 is identical to the one or more first stent segments 100 except for the taper.
  • the stent segments 100, 200 and 300 are secured in position by the graft material.
  • the first, second and third stent segments 100, 200, 300 are preferably self-expandable and formed from a shape memory alloy. Such an alloy may be deformed from an original, heat-stable configuration to a second, heat-unstable configuration. The application of a desired temperature causes the alloy to revert to an original heat-stable configuration.
  • a particularly preferred shape memory alloy for this application is binary nickel titanium alloy comprising about 55.8 percent Ni by weight, commercially available under the trade designation NITINOL. This NiTi alloy undergoes a phase transformation at physiological temperatures.
  • a stent made of this material is deformable when chilled. Thus, at low temperatures, for example, below twenty degrees centigrade, the stent is compressed so that it can be delivered to the desired location.
  • the stent may be kept at low temperatures by circulating chilled saline solutions. The stent expands when the chilled saline is removed and it is exposed to higher temperatures within the patient's body, generally around thirty-seven degrees centigrade.
  • each stent is fabricated from a single piece of alloy tubing.
  • the tubing is laser cut, shape-set by placing the tubing on a mandrel, and heat-set to its desired expanded shape and size.
  • the shape setting is performed in stages at five hundred degrees centigrade. That is, the stents are placed on sequentially larger mandrels and briefly heated to five hundred degrees centigrade. To minimize grain growth, the total time of exposure to a temperature of five hundred degrees centigrade is limited to five minutes. The stents are given their final shape set for four minutes at five hundred fifty degrees centigrade, and then aged to a temperature of four hundred seventy degrees centigrade to import the proper martensite to austenite transformation temperature, then blasted, as described in detail subsequently, before electropolishing. This heat treatment process provides for a stent that has a martensite to austenite transformation which occurs over a relatively narrow temperature range; for example, around fifteen degrees centigrade.
  • the rough edges left by the laser cutting are removed by combination of mechanical grit blasting and electropolishing.
  • the grit blasting is performed to remove the brittle recast layer left by the laser cutting process. This layer is not readily removable by the electropolishing process, and if left intact, could lead to a brittle fracture of the stent struts.
  • a solution of seventy percent methanol and thirty percent nitric acid at a temperature of minus forty degrees centgrade or less has been shown to work effectively as an electropolishing solution.
  • Electrical parameters of the electropolishing are selected to remove approximately 0.00127 cm of material from the surfaces of the struts.
  • the clean, electropolished surface is the final desired surface for attachment to the graft materials. This surface has been found to import good corrosion resistance, fatigue resistance, and wear resistance.
  • the graft material or component 400 may be made from any number of suitable biocompatible materials, including woven, knitted, sutured, extruded, or cast materials comprising polyester, polytetrafluoroethylene, silicones, urethanes, and ultralight weight polyethylene, such as that commercially available under the trade designation SPECTRA.
  • the materials may be porous or nonporous.
  • Exemplary materials include a woven polyester fabric made from DACRON or other suitable PET-type polymers.
  • the fabric for the graft material is a forty denier (denier is defined in grams of nine thousand meters of a filament or yarn), twenty-seven filament polyester yarn, having about seventy to one-hundred end yarns per cm per face and thirty-two to forty-six pick yarns per cm face. At this weave density, the graft material is relatively impermeable to blood flow through the wall, but is relatively thin, ranging between 0.08 and 0.12 mm in wall thickness.
  • the graft component 400 is a single lumen tube and preferably has a taper and flared portion woven directly from the loom, as illustrated for the endovascular graft 10 shown in Figure 1.
  • crimps Prior to attachment of the graft component 400 to the stents 100, 200, 300, crimps are formed between the stent positions by placing the graft material on a shaped mandrel and thermally forming indentations in the surface.
  • the crimps 402 in the graft 400 are about two mm long and 0.5 mm deep. With these dimensions, the endovascular graft 10 can bend and flex while maintaining an open lumen.
  • the graft material is cut in a shape to mate with the end of each end stent.
  • each of the stent segments 100, 200 and 300 is attached to the graft material 400.
  • the graft material 400 may be attached to the stent segments 100, 200, 300 in any number of suitable ways.
  • the graft material 400 may be attached to the stent segments 100, 200, 300 by sutures.
  • the method of suturing stents in place is important for minimizing the relative motion or rubbing between the stent struts and the graft material. Because of the pulsatile motion of the vasculature and therefore the graft system, it is possible for relative motion to occur, particularly in areas where the graft system is in a bend, or if there are residual folds in the graft material, due to being constrained by the aorta or iliac arteries.
  • each strut of each stent segment is secured to the graft material by sutures.
  • the suture material is blanket stitched to the stent segments at numerous points to securely fasten the graft material to the stent segments.
  • a secure hold is desirable in preventing relative motion in an environment in which the graft system experiences dynamic motion arising from pulsatile blood pressure, in addition to pulsation of the arteries that are in direct mechanical contact with the graft system.
  • the stents nearest the aortic and iliac ends of the graft system are subject to the pulsatile motion arising from direct internal contact.
  • the stitches 404 on the upper most first stent segment 100 are positioned along the entire zigzag arrangement of struts.
  • the upper and lower apexes of the third stent segment may be stitched utilizing a similar configuration. It is difficult to manipulate the suture thread precisely around the struts that are located some distance away from an open end, accordingly, various other simpler stitches may be utilized on these struts, or no stitches may be utilized in these areas.
  • each of the struts in the first stent segment 100 is secured to the graft material 400 which has been cut to match the shape of the stent segment 100.
  • the blanket stitching 404 completely encircles the strut and bites into the graft material 400.
  • the stitch 404 encircles the strut at approximately five equally spaced locations.
  • Each of the struts on each end of the third stent segment 300 is attached to the graft material, which has been cut to make the shape of the stent segment 300, in the same manner as the first stent segment 100.
  • a significant portion of the graft will not rest directly against vascular tissue. This portion of the graft will be within the dilated aneurysm itself. Therefore, this portion of the graft will not experience any significant pulsatile motion. For this reason, it is not necessary to secure the stent segments to the graft material as aggressively as the stent structure described above. Therefore, only point stitches 406 are necessary for securing these stents.
  • Typical stent-grafts are fabricated from a woven polyester and are approximately 0.127 mm (0.005 inches) thick.
  • a stent-graft fabricated from a woven polyester low twist, forty denier, twenty-seven filament yarn having two-hundred thirty yarn ends per inch and one hundred yarn picks per inch results in a graft material having a wall thickness of approximately 0.127 mm (0.005 inches).
  • the graft material is then attached to the inside or outside of a stent or multiple stent segments as described above. Appreciable gains may be achieved in having a graft material thickness in the range from about 0.051 mm (0.002 inches) to about 0.076mm (0.003 inches).
  • the wall thickness is determined primarily by weave density and yarn thickness or bulkiness. It is desirable to have a graft which is packed tight enough to prevent significant blood seepage, but not so tight that the yarn bundles pile up on each other.
  • the weaving parameters described above result in just such a graft for the particular yarn described. At this density, the graft material is about as thin walled as it can be without significant permeability. Also, the yarn described above is only lightly twisted, so as the yarn bundles cross over one another, they tend to flatten out. Higher twisting would both make the graft more permeable and thicker, and the yarn bundle would tend to remain cylindrical at the crossover points. The only remaining parameter that can be utilized to thin the graft is smaller yarn bundles.
  • the forty denier, twenty-seven filament polyester yarn described above has a relatively small filament size and a relatively low number of filaments. However, in theory, a much smaller yarn bundle could be contemplated with either few filaments, smaller filaments, or both. For example, a twenty denier yarn bundle could be made from fourteen filaments of the same diameter as described above. If this yarn were woven into a graft material with an appropriately dense weave, one would expect a graft material having a thickness of approximately 0.063 mm (0.0025 inches). While this may work as an acceptable graft, it is possible that the long-term integrity of such a graft may not be acceptable due to the forces described above.
  • the graft material may be formed utilizing any number of techniques, including weaving, knitting and braiding. Weaving involves the interlacing, at right angles, of two systems of threads known as warp and filling. Warp threads run lengthwise in a woven fabric and filling threads run cross-wise. Knitting is the process of making fabric by interlocking a series of loops of one or more threads. Braiding involves crossing diagonally and lengthwise several threads of any of the major textile fibers to obtain a certain width effect, pattern or style.
  • graft material may be attached to the stent, for example, polymeric sutures. Accordingly, it may be possible to simply create a thinner polyester graft material as described above, more tightly secure it to the stent in areas which exhibit the greatest potential for micro-motion, and have a lower profile, longer wear resistant stent-graft.
  • alternate materials for fabricating a significantly thinner graft material with high wear resistance Higher strength and/or tougher materials may yield a much thinner stent-graft conduit without sacrificing long-term integrity.
  • some of the materials that may be utilized are so much stronger and tougher than polyester sold under the mark Dacron, that a significantly thinner stent-graft constructed of these materials may be substantially stronger and more wear resistant than currently available stent-grafts.
  • polyester sold under the mark Dacron has a tenacity of approximately nine grams per denier
  • high performance fibers have tenacities in the range from about thirty-five to about forty-five grams per denier.
  • the more preferred fibers from a strength standpoint for consideration for use in an ultra thin walled stent-graft material, approximately, 0.051 to 0.076 mm (0.002 to 0.003 inches) include polyaramid, polyphynelenebenzobisoxazole, liquid crystal polymer and ultra high molecular weight polyethylene.
  • ultra high molecular weight polyethylene fibers may offer a slight advantage in the fact that their basic chemistry is polyethylene, which is known to be relatively inert in biological applications.
  • Another important consideration for the above-described fibers is their availability in fine denier yarns. With current stent-grafts fabricated from a forty denier polymer yarn, it would be difficult to fabricate a stent-graft having thinner walls unless the yarn is of a finer denier.
  • a liquid crystal polymer sold under the tradename Vectran is available as a twenty-five denier yarn.
  • a ultra high molecular weight polyethylene sold under the tradename Spectra is available as a thirty-denier yarn.
  • Another ultra high molecular weight polyethylene sold under the tradename Dyneema is available as a twenty to twenty-five denier yarn.
  • ultra high molecular weight polyethylene fibers only have a density of 0.97 versus 1.38, so that the same denier yarn would be bulkier in ultra high molecular weight polyethylene, however, due to the substantial improvement in tensile and abrasive properties, much less ultra high molecular weight polyethylene would be necessary to obtain equivalent material properties.
  • Ultra high molecular weight polyethylene typically has between six and twelve million ethylene units per molecule. Ultra high molecular weight polyethylene has a low coefficient of friction, a high molecular weight and a high density. Accordingly, a fabric made from ultra high molecular weight polyethylene is highly abrasion resistant, highly impact resistant, and highly resistant to damage by water, salt or fresh. Ultra high molecular weight polyethylene monofilaments have a high tensile strength with the associated advantage of stretch resistance and elasticity. These properties make it especially suitable for tortuous body passageways.
  • ultra high molecular weight polyethylene is the preferred yarn for use as a graft material.
  • the ultra high molecular weight polyethylene yarn may be woven, knitted or braided to form the graft material and attached to the one or more stent segments as described above.
  • the graft material may also be used as a strand alone device for surgical applications or combined with the one or more stents for endovascular delivery.
  • the ultra high molecular weight polyethylene yarn may be blended with a dissimilar material, for example, Dacron® polyester, to manufacture a graft material with altered bulk properties; e.g., stretch potential, while retaining strength and abrasion resistance.
  • the monofilament of ultra high molecular weight polyethylene may be blended together with another material to attain a true blended yarn such that a fiber or monofilament of one material can be placed next to a monofilament of a second material (third, fourth...) to create a resultant yarn which possesses properties that differ from each of its monofilaments.
  • graft material may be attached to stents or stent segments in any number of suitable ways.
  • the graft material may be attached by suturing the graft material to the stent lattice at predetermined locations as described herein.
  • the graft material may be attached to the stent or stent segments via an attachment device that holds or sandwiches the graft material between itself and a portion of the stent. In this approach, the graft material is not punctured.
  • the attachment device may comprise any suitable configuration such as a band or clip and may be formed from any suitable material. It is important to note that the attachment device may be utilized for applications other than the attachment of graft material to stents or stent segments. For example, the attachment device may be utilized to attach or secure any substantially flexible material or covering to another element or substrate.
  • FIGS 5a-5d there is illustrated an exemplary attachment device 500 in accordance with the present invention.
  • Figures 5a-5d illustrate a progression of cross-sectional views of the attachment device 500, a segment of a stent 502, and a segment of graft material 504 as the attachment device 500 is positioned and secured into place.
  • the attachment device 500 is positioned over the graft material 504 and a segment of a stent 502.
  • the attachment device 500 may comprise any suitable shape, size and material.
  • the attachment device 500 comprises a shape and material that allows it to be positioned over the graft material 504 and stent segment 502 and then crimped or otherwise manipulated into a configuration such that it substantially conforms to the shape of the stent segment 502 as illustrated in Figure 5d. With this snug fit, the overall profile of the stent-graft or other device will not be significantly impacted or affected.
  • the attachment device 500 preferably comprises a material that exhibits minimal fatigue wear when undergoing the crimping process.
  • the attachment device 500 comprises a simple band, clip or ring structure formed by creating a longitudinal slit or opening in a tubular structure.
  • the slit or opening may be formed by any suitable machining technique.
  • the attachment device 500 may be formed from any suitable material, including plastics and metals.
  • the attachment device may comprise polymeric materials or various metallic materials such as stainless steel or tantalum.
  • it may be desirable to utilize a highly radiopaque material for the attachment device 500 so that it may serve the dual purpose of securing the graft material to the stent and act as a marker band for properly deploying the stent-graft in position.
  • Metallic materials such as tantalum are highly radiopaque. If the stent is formed from a highly radiopaque material or utilizes other marker elements, then any other suitable material may be utilized for the attachment device 500.
  • the attachment device 500 may be formed by mechanical shape setting of a thermal or shape memory material or by ultrasonic welding.
  • the attachment device 500 may be crimped snuggly around the stent segment 502 as illustrated in the progression of Figures 5a through 5d. As illustrated in Figure 5d, the attachment device 500 securely holds the graft material 504 to the stent segment 502 without creating any openings in the graft material 504.
  • the attachment device 500 may be utilized anywhere the sutures described above may be utilized.
  • the shape and/or size of the attachment devices 500 may vary depending on their location on the stent or stent segment so that exact positioning may be achieved.
  • the graft material 504 may be securely held in position and the overall profile of the stent-graft will not be significantly impacted.
  • the thickness of the attachment device 500 may be maintained to less than that of the suture/suture knot.
  • the attachment device 500 and/or the stent segment 502 may be modified such that the attachment device 500 slips or gives as the stent moves.
  • some or all of the attachment devices 500 may be fixed in position by complete crimping or some or all of the attachment devices 500 may be slidably mounted to accommodate stent lengthening during crimping.
  • the attachment devices 500 may be slidably mounted by less than complete crimping, by designing the attachment devices 500 to allow movement even when fully crimped or by modifying some or all of the stent segments.
  • a stent segment 602 having a reduced profile section 604 that would allow the attachment device 500 to move in that area, but not beyond the area.
  • the attachment device 500 comprises a simple band, clip or ring structure formed from a tube with a longitudinal slit.
  • the slit is expanded to fit over the stent element, for example, the stent struts, and graft material, and then crimped, squeezed or deformed to wrap around the strut and graft material.
  • the attachment device 500 may also be made of a tubular structure that is bent or deformed into a substantially kidney shape, then placed and crimped. This design would preferably minimize and damage caused by any potential sharp edges formed during crimping. Similar shapes such as a disc could be used and formed to wrap around the stent segment and graft material.
  • the attachment device 500 may be utilized for attaching an implantable graft material to a stent such as used in the fabrication of a covered stent, stent-graft, endoleg or any other device that requires a covering to be attached to a substrate.
  • the attachment device 500 comprises a hypotube segment that has a slit or slice cut longitudinally such that as to create an opening for accepting the stent and graft fabric.
  • the attachment device 500 is fitted onto the stent strut 502 and graft material 504 by slipping the stent 502 and graft material 504 through the slit as illustrated in Figure 5a. Then the attachment device 500 is crimped to capture or hold the stent 502 and graft material 504 together as illustrated in Figure 5d.
  • Figures 7a-c illustrate an exemplary crimping tool 700 that may be utilized to squeeze or crimp the attachment device 500 and deform it into its final shape.
  • the crimping tool 700 comprises a pair of pivotally moveable jaws 702,704.
  • the jaws 702,704 are opened a distance sufficient to fit around the attachment device 500, the stent strut 502 and the graft material 504 as illustrated in Figure 7a.
  • the jaws 702,704 are pivoted together, as illustrated in Figure 7b, until the attachment device 500 fits snuggly around the stent strut 502 and graft material 504, as illustrated in Figure 7c.
  • the jaws 702,704 of the crimping tool 700 may comprise any suitable configuration and may be formed from any suitable material.
  • the crimping tool 700 is preferably configured like pliers with jaws 702,704 being configured to the shape of stent struts. Accordingly, different crimping tools 700 may be employed with stents having different struts shapes.
  • the crimping tool 700 may be configured such that the jaws 702,704 are interchangeable or that they may be fitted with inserts that conform to the shape of the particular strut.
  • the crimping tool 700 may comprise a means for limiting the pressure applied to the struts and graft material.
  • the crimping tool 700 may comprise a mechanical stop that limits the composition of the jaws 702,704 or an adjustable stop similar to mechanism utilized in vise grips.
  • the attachment device of the present invention may be utilized to attach graft material or graft like material to any number of medical devices.
  • the above-described stents and graft material ( Figures 1-4) are for illustrative purposes and not intended to limit the scope of the claimed invention.
  • the attachment device of the present invention may be utilized with any stent and with any graft material, or as stated above, the attachment device may be utilized to attach or secure any substantially flexible material or covering to another element or substrate.
  • the attachment device of the present invention offers a number of substantial advantages over existing attachment technology.
  • the attachment device would be insulated from the stent framework by a layer of graft material which in turn reduces or substantially eliminates bimetallic coupling thus reducing or substantially eliminating the risk of galvanic corrosion.
  • the attachment device does not require a breach of the graft material to secure the graft to the stent. This eliminates the suture or staple holes that are created with attachments of other designs and greatly reduces the chance of leaking through at the attachment sites. No portion of the attachment device needs to be placed interior of the graft material and therefore if an attachment device failed in a long term situation it would be captured or trapped between the outside of the stent graft and the vessel wall minimizing the chance of particle emboli.
  • the manufacture of a stent graft utilizing the attachment device of the present invention is greatly simplified since all assembly work may be done from the exterior of the stent.
  • the attachment device of the present invention is a low profile device and may serve a dual role as a connection means and radiopaque marker.
  • attachment device 500 of the present invention may be utilized alone or in combination with other attachment means including sutures and/or staples as described above.

Abstract

An attachment device (500) is described which comprises a deformable, partially tubular band (504) having a slotted opening for accepting a portion of a first substantially flexible element and a portion of a second substrate element (502).
A stent graft (10) is also described which comprises: one or more stent structures; a biocompatible graft material affixed to the one or more stent structures; and at least one attachment device for securing the biocompatible graft material to the one or more stent structures.
The stent-graft can be fabricated from a thin-walled, high strength material which provides for a more durable and lower profile endoprosthesis. The stent-graft can comprise one or more stent segments covered with a fabric formed by the weaving, knitting or braiding of a biocompatible, high tensile strength, abrasion resistant, highly durable yarn such as ultra high molecular weight polyethylene. The one or more stent segments may be balloon expandable or self-expanding. The fabric may be attached to the stent segments utilizing an attachment device that secures the fabric to a strut of the stent segment by sandwiching the fabric between itself and the stent strut.

Description

  • The present invention relates to devices and methods for repairing aneurysms and more particularly, to percutaneously and/or intraluminally delivered devices and methods for repairing aneurysms such as abdominal aortic aneurysms and thoracic aortic aneurysms. The present invention also relates to devices utilized to attach graft material to stents or other substrates for fabricating devices for repairing aneurysms and the like.
  • An aneurysm is an abnormal dilation of a layer or layers of an arterial wall, usually caused by a systemic collagen synthetic or structural defect. An abdominal aortic aneurysm is an aneurysm in the abdominal portion of the aorta, usually located in or near one or both of the two iliac arteries or near the renal arteries. The aneurysm often arises in the infrarenal portion of the diseased aorta, for example, below the kidneys. A thoracic aortic aneurysm is an aneurysm in the thoracic portion of the aorta. When left untreated, the aneurysm may rupture, usually causing rapid fatal hemorrhaging.
  • Aneurysms may be classified or typed by their position as well as by the number of aneurysms in a cluster. Typically, abdominal aortic aneurysms may be classified into five types. A Type I aneurysm is a single dilation located between the renal arteries and the iliac arteries. Typically, in a Type I aneurysm, the aorta is healthy between the renal arteries and the aneurysm and between the aneurysm and the iliac arteries.
  • A Type II A aneurysm is a single dilation located between the renal arteries and the iliac arteries. In a Type II A aneurysm, the aorta is healthy between the renal arteries and the aneurysm, but not healthy between the aneurysm and the iliac arteries. In other words, the dilation extends to the aortic bifurcation. A Type II B aneurysm comprises three dilations. One dilation is located between the renal arteries and the iliac arteries. Like a Type II A aneurysm, the aorta is healthy between the aneurysm and the renal arteries, but not healthy between the aneurysm and the iliac arteries. The other two dilations are located in the iliac arteries between the aortic bifurcation and the bifurcations between the external iliacs and the internal iliacs. The iliac arteries are healthy between the iliac bifurcation and the aneurysms. A Type II C aneurysm also comprises three dilations. However, in a Type II C aneurysm, the dilations in the iliac arteries extend to the iliac bifurcation.
  • A Type III aneurysm is a single dilation located between the renal arteries and the iliac arteries. In a Type in aneurysm, the aorta is not healthy between the renal arteries and the aneurysm. In other words, the dilation extends to the renal arteries.
  • A ruptured abdominal aortic aneurysm is presently the thirteenth leading cause of death in the United States. The routine management of abdominal aortic aneurysms has been surgical bypass, with the placement of a graft in the involved or dilated segment. Although resection with a synthetic graft via transperitoneal or retroperitoneal procedure has been the standard treatment, it is associated with significant risk. For example, complications include perioperative myocardial ischemia, renal failure, erectile impotence, intestinal ischemia, infection, lower limb ischemia, spinal cord injury with paralysis, aorta-enteric fistula, and death. Surgical treatment of abdominal aortic aneurysms is associated with an overall mortality rate of five percent in asymptomatic patients, sixteen to nineteen percent in symptomatic patients, and is as high as fifty percent in patients with ruptured abdominal aortic aneurysms.
  • Disadvantages associated with conventional surgery, in addition to the high mortality rate, include an extended recovery period associated with the large surgical incision and the opening of the abdominal cavity, difficulties in suturing the graft to the aorta, the loss of the existing thrombosis to support and reinforce the graft, the unsuitability of the surgery for many patients having abdominal aortic aneurysms, and the problems associated with performing the surgery on an emergency basis after the aneurysm has ruptured. Further, the typical recovery period is from one to two weeks in the hospital and a convalescence period, at home, ranging from two to three months or more, if complications ensue. Since many patients having abdominal aortic aneurysms have other chronic illnesses, such as heart, lung, liver and/or kidney disease, coupled with the fact that many of these patients are older, they are less than ideal candidates for surgery.
  • The occurrence of aneurysms is not confined to the abdominal region. While abdominal aortic aneurysms are generally the most common, aneurysms in other regions of the aorta or one of its branches are possible. For example, aneurysms may occur in the thoracic aorta. As is the case with abdominal aortic aneurysms, the widely accepted approach to treating an aneurysm in the thoracic aorta is surgical repair, involving replacing the aneurysmal segment with a prosthetic device. This surgery, as described above, is a major undertaking, with associated high risks and with significant mortality and morbidity.
  • Over the past five years, there has been a great deal of research directed at developing less invasive, endovascular, i.e., catheter directed, techniques for the treatment of aneurysms, specifically abdominal aortic aneurysms. This has been facilitated by the development of vascular stents, which can and have been used in conjunction with standard or thin-wall graft material in order to create a stent-graft or endograft. The potential advantages of less invasive treatments have included reduced surgical morbidity and mortality along with shorter hospital and intensive care unit stays.
  • Stent-grafts or endoprostheses are now Food and Drug Administration (FDA) approved and commercially available. Their delivery procedure typically involves advanced angiographic techniques performed through vascular accesses gained via surgical cutdown of a remote artery, which may include the common femoral or brachial arteries. Over a guidewire, the appropriate size introducer will be placed. The catheter and guidewire are passed through the aneurysm. Through the introducer, the stent-graft will be advanced to the appropriate position. Typical deployment of the stent-graft device requires withdrawal of an outer sheath while maintaining the position of the stent-graft with an inner-stabilizing device. Most stent-grafts are self-expanding; however, an additional angioplasty procedure, e.g., balloon angioplasty, may be required to secure the position of the stent-graft. Following the placement of the stent-graft, standard angiographic views may be obtained.
  • Due to the large diameter of the above-described devices, typically greater than twenty French (3F=1 mm), arteriotomy closure typically requires open surgical repair. Some procedures may require additional surgical techniques, such as hypogastric artery embolization, vessel ligation, or surgical bypass in order to adequately treat the aneurysm or to maintain blood flow to both lower extremities. Likewise, some procedures will require additional advanced catheter directed techniques, such as angioplasty, stent placement and embolization, in order to successfully exclude the aneurysm and efficiently manage leaks.
  • While the above-described endoprostheses represent a significant improvement over conventional surgical techniques, there is a need to improve the endoprostheses, their method of use and their applicability to varied biological conditions. Accordingly, in order to provide a safe and effective alternate means for treating aneurysms, including abdominal aortic aneurysms and thoracic aortic aneurysms, a number of difficulties associated with currently known endoprostheses and their delivery systems must be overcome. One concern with the use of endoprostheses is the prevention of endo-leaks and the disruption of the normal fluid dynamics of the vasculature. Devices using any technology should preferably be simple to position and reposition as necessary, should preferably provide an acute, fluid tight seal, and should preferably be anchored to prevent migration without interfering with normal blood flow in both the aneurysmal vessel as well as branching vessels. In addition, devices using the technology should preferably be able to be anchored, sealed, and maintained in bifurcated vessels, tortuous vessels, highly angulated vessels, partially diseased vessels, calcified vessels, odd shaped vessels, short vessels, and long vessels. In order to accomplish this, the endoprostheses should preferably be highly durable, extendable and re-configurable while maintaining acute and long-term fluid tight seals and anchoring positions.
  • The endoprostheses should also preferably be able to be delivered percutaneously utilizing catheters, guidewires and other devices which substantially eliminate the need for open surgical intervention. Accordingly, the diameter of the endoprostheses in the catheter is an important factor. This is especially true for aneurysms in the larger vessels, such as the thoracic aorta.
  • The present invention overcomes the potential disadvantages associated with percutaneously delivered endoprostheses as briefly described above.
  • In accordance with one aspect, the present invention is directed to an attachment device. The attachment device comprises a deformable, partially tubular band having a slotted opening for accepting a portion of a first substantially flexible element and a portion of a second substrate element.
  • In accordance with another aspect, the present invention is directed to a stent graft. The stent graft comprises one or more stent structures, a biocompatible graft material affixed to the one or more stent structures, and at least one attachment device for securing the biocompatible graft material to the one or more stent structures. The at least one attachment device comprising a deformable, partially tubular band having a slotted opening for accepting a portion of the one or more stent structures and a portion of the biocompatible graft material.
  • In accordance with another aspect, the present invention is directed to a method for attaching graft material to a stent structure. The method comprises positioning graft material around a stent structure, positioning at least one attachment device such that the graft material is sandwiched between the at least one attachment device and a portion of the stent structure, and crimping the at least one attachment device around the graft material at the portion of the stent structure.
  • The abrasion resistant stent-graft of the present invention comprises at least one stent segment and a highly durable, abrasion-resistant graft material attached thereto. The graft material may be attached to the at least one stent segment in any number of ways. The stent-graft may be utilized as a component of a larger system, for example, in a system for repairing abdominal aortic aneurysms, or as a stand-alone device. In either embodiment, the stent-graft is utilized as a fluid carrying conduit that is preferably percutaneously delivered, but may also be utilized surgically. The at least one stent segment may comprise any suitable scaffold structure and may be fabricated from any number of biocompatible materials. The at least one stent segment may be self-expanding or balloon expandable.
  • The abrasion resistant stent-graft of the present invention is preferably percutaneously delivered, and as such it is preferably designed with the smallest diameter possible. In order to achieve the smallest diameter possible, thinner graft materials are needed. However, stent-grafts are typically positioned within the body in vessels that have relatively high hydrodynamic forces, thus requiring graft materials which are able to withstand these forces. Essentially, these forces tend to wear the graft material at the points where it is connected to the at least one stent segment. Over time, the graft material may develop microleaks which obviously defeat the purpose of the stent-graft, namely, as a by-pass conduit. Accordingly, the abrasion resistant stent-graft of the present invention utilizes a biocompatible, high tensile strength, abrasion resistant, highly durable yarn which may be woven, knitted or braided into a graft material without sacrificing diameter.
  • The yarn or thread may comprise a single component or it may be blended with one or more other suitable materials to achieve various desirable characteristics, including abrasion resistance, flexibility and thinness. One such yarn comprises ultra high molecular weight polyethylene, which is commercially available. Accordingly, the abrasion resistant stent-graft of the present invention is a highly durable stent-graft which, because of its thin graft material, may be percutaneously delivered more easily than present stent-grafts.
  • The attachment device of the present invention comprises a clip or band structure that may be utilized to attach graft material to a stent thereby forming a covered stent, stent-graft, endoleg, endoprosthesis or any other device that requires a covering to be attached to a substrate. The attachment device may be fitted over the graft material and a segment of the stent, such as a stent strut, and then deformed to create a snug fit around the stent segment with the graft material sandwiched therebetween. A device, similar to pliers, may be utilized to deform or crimp the attachment device to the stent segment.
  • The attachment device of the present invention may be utilized to secure or attach graft material to a stent or stent like structure without the need for sutures or staples as is currently utilized. Alternately, the attachment device of the present invention may be utilized in combination with other securing means such as staples or sutures.
  • The attachment device of the present invention offers a number of advantages over existing attachment technology. The attachment device does not make direct contact with the stent because the graft material is sandwiched therebetween. If the attachment device were constructed from a metallic material different from the metallic material comprising the stent, and if the two components were in direct contact, there may be corrosion due to galvanic action. The attachment device does not require a breach of the graft material. Accordingly, there is less likely of a chance of leakage and graft failure due to tearing. The attachment device is positioned on the surface of the stent-graft that is in contact with the vessel wall; therefore, in the unlikely even the attachment device becomes dislodged, it will be trapped between the vessel wall and the stent-graft and pose substantially no threat of creating a particle emboli. The attachment device may serve a dual role. If needed, the attachment device may be fabricated from a highly radiopaque material and function as a marker band for proper placement of the stent-graft.
  • The attachment device of the present invention is simple and inexpensive to manufacture. The attachment device is also simple to utilize.
  • The present invention is directed to an endovascular graft which may be utilized as a component in a system for use in treating or repairing aneurysms. Systems for treating or repairing aneurysms such as abdominal aortic aneurysms and thoracic aortic aneurysms come in many forms. A typical system includes an anchoring and/or sealing component which is positioned in healthy tissue above the aneurysm and one or more grafts which are in fluid communication with the anchoring and/or sealing component and extend through the aneurysm and anchor in healthy tissue below the aneurysm. Essentially, the grafts are the components of the system that are utilized to establish a fluid flow path from one section of an artery to another section of the same or different artery, thereby bypassing the diseased portion of the artery. Current systems are preferably percutaneously delivered and deployed.
  • As stated above, the present invention is directed to one component of an aneurysm repair system; namely, the endovascular graft of stent-graft. Accordingly, the following detailed description is directed to the endovascular graft. The endovascular graft comprises at least one stent segment and a highly durable, abrasion-resistant graft material attached thereto. In other words, the endovascular graft of the present invention is supported internally by one or more individual stents, which are themselves connected to the graft in a manner which secures their position, for example, by sutures. It is important to note that while one particular stent design is discussed in detail below, the graft of the present invention may incorporate any number of suitable stent designs, including self-expanding stents and balloon expandable stents. In addition, the endovascular graft may comprise a device formed solely from the graft material.
  • Embodiments of the invention will now be described by way of example only with reference to the accompanying drawings, in which:
  • Figure 1 is an elevational view of an endovascular graft in accordance with the present invention;
  • Figure 2 is a perspective view of an expanded stent segment of the endovascula graft in accordance with the present invention;
  • Figure 2A is a fragmentary perspective view of a portion of the stent segment of Figure 2;
  • Figure 2B is a fragmentary perspective view of a portion of the stent segment of Figure 2;
  • Figure 2C is an enlarged plan view of a section of the stent segment of Figure 2;
  • Figure 2D is an enlarged plan view of a section of the stent segment of Figure 2;
  • Figure 3 is a perspective view of another expanded stent segment of the endovascular graft in accordance with the present invention;
  • Figure 4 is an elevational view of an endovascular graft in accordance with the present invention;
  • Figures 5a-5d, are sectional views of the attachment device in accordance with the present invention;
  • Figure 6 is a sectional view of a modified stent segment in accordance with the present invention;
  • Figures 7a-c are diagrammatic representations of a crimping device in accordance with the present invention;
  • Figure 1 illustrates an exemplary embodiment of an endovascular graft 10 in accordance with the present invention. The exemplary endovascular graft 10 comprises one or more first stent segments 100, one second stent segment 200 and a third stent segment 300. In order to illustrate the relationship of the various components comprising the endovascular graft 10, the endovascular graft is illustrated in the figure as though the graft material were transparent. In a typical use scenario, the third stent segment 300 would be anchored in healthy tissue below the aneurysm and the uppermost first stent segment 100 would be in fluid communication with an anchoring and/or sealing component as briefly described above. It is important to note, however, that depending on the design of the system, an anchoring and/or sealing component may not be necessary. The second stent segment 200 comprises a tapered profile, having a diameter at one end equal to that of the first stent segments 100 and a diameter at the other end equal to that of the third stent segment 300. The length of the endovascular graft may be varied by the number of first stent segments 100 utilized.
  • Figure 2 is a detailed perspective view of an exemplary embodiment of the third stent segment 300. The third stent segment 300 comprises a plurality of struts 302 connected in a substantially zigzag pattern. As illustrated, the exemplary third stent segment 300 comprises three sets of zigzag-connected stents 302, thereby forming substantially diamond-shaped cells. The non- connected apex 304 of each diamond shaped cell, illustrated in greater detail in Figure 2A, comprises a smooth, uniform width curved region formed at the intersection of two stents 302 of each diamond-shaped cell. This shape is cut directly into the stent segment 300 during the initial machining steps, typically laser cutting, as is explained in detail subsequently, and is maintained during all subsequent finishing processing. The junctions 306 between the zigzag- connected stents 302, illustrated in greater detail in Figure 2B occurs at the intersection of four struts 302. Preferably, each junction 306 of four struts 302 comprises two indentations 308 and 310 as illustrated in Figure 2B.
  • The regions proximate the non-connected apexes 304 and the junctions 306 are generally the highest stress regions in the third stent segment 300. To minimize the stresses in these regions, these regions are designed to maintain uniform beam widths proximate where the struts 302 interconnect. Beam width refers to the width of a strut 306. Indentations 308 and 310 are cut or machined into the junctions 306 to maintain a uniform beam width in this area, which is generally subject to the highest stress. Essentially, by designing the junctions 306 to maintain uniform beam widths, the stress and strain that would normally build up in a concentrated area, proximate the junction 306, is allowed to spread out into the connecting regions, thereby lowering the peak values of the stress and strain in the stent structure.
  • To further minimize the maximum stresses in the struts 302 of the third stent segment 300, the struts 302 may have a tapering width. For example, in one exemplary embodiment, the struts 302 may be designed to become wider as it approaches a junction 306. Figure 2C is an enlarged partial view of the third sent segment 300 in its expanded conditions which illustrates the tapering width of the struts 302. In this exemplary embodiment, the strut 302 proximate the junction 306 (width a) is about 0.025 cm and gradually tapers to a dimension of about 0.0178 cm in the mid-region of the strut 302 (width b). By tapering the struts' widths, the stresses in the struts 302 adjacent the junction 306 is spread out away from the junction 306. The tapering of the struts 302 is accomplished during the machining of the tube of material from which the stent 300 is cut, as described in detail subsequently. However, by tapering the struts 302 in this manner, there is a tradeoff. The stent segment 300 becomes somewhat less resistant to localized deformations, caused for example, by a protrusion within the vessel lumen. This localized deformation may lead to a local torsional loading on some of the struts 302, and, therefore, since the struts 302 in this exemplary embodiment have a relatively significant portion of their length with a reduced width, their torsional rigidity is reduced.
  • If maximizing the resistance to localized deformation is preferred, the struts 302 may be maintained at a uniform width, or more preferably have a reverse taper, as illustrated in Figure 2D, wherein the width at point a is less than the width at point b. In this exemplary embodiment, the reverse taper struts 302 are about 0.025 cm proximate the junction 306 and about 0.028 cm in the central region of the struts. While this reverse taper tends to increase the stresses somewhat proximate the junctions 306, this increase is very small relative to the decrease in stresses gained by having the side indentations 308, 310 illustrated in Figure 2B, as well as the uniform width connections illustrated in Figure 2A. In addition, since the reverse taper serves to increase the torsional rigidity of the strut 302, the stent structure resists local deformation and tends to maintain a substantially circular cross-sectional geometry, even if the lumen into which the stent is positioned in non-circular in cross-section.
  • In a preferred exemplary embodiment, the third stent segment 300 is fabricated from a laser cut tube, as described in detail subsequently, of initial dimensions 0.229 cm inside diameter by 0.318 cm outside diameter. The struts 302 are preferably 0.0229 cm wide adjacent the four strut junctions 306 and six mm long, with a reverse taper strut width. Also, to minimize the number of different diameter combination of grafts systems, it is preferred that the third stent segment 300 have an expanded diameter of sixteen mm. Similarly, the proximal portion of the graft material forming the legs is flared, having a diameter of sixteen mm. This single diameter for the third stent segment of the graft system would enable its use in arteries having a non-aneurysmal region of a diameter from between eight and fourteen mm in diameter. It is also contemplated that multiple diameter combinations of third stent segment 300 and graft flare would be desirable.
  • Referring back to Figure 1, the one or more first stent segments 100 are also formed from a shape set laser cut tube, similar to the third stent segment 300 described above. The one or more first stent segments 100 comprise a single circumferential row of zigzag or sinusoidally arranged elements. In the exemplary embodiment illustrated in Figure 1, and in greater detail in Figure 3, the first stent segment 100 comprises ten zigzag or sinusoidal undulations. The one or more first stent segments 100 are formed with uniform width connections at the intersections 104 of the struts 102 forming the zigzag or sinusoidal pattern. The one or more first stent segments 100 are preferably cut from tubing having an inside diameter of 0.251 cm and an outside diameter of 0.317 cm. The strut widths are preferably about 0.33 cm wide adjacent strut intersections 104 and the struts 102 are preferably seven mm long and the one or more first stent segments 100 are preferably eleven mm in diameter when expanded.
  • Referring back to Figure 1, the second stent segment 200 comprises a tapered profile, having a diameter at one end which is the same as the one or more first stent segments 100, and a diameter at the other end matching the diameter of the third stent segment 300. The second stent segment 200 is identical to the one or more first stent segments 100 except for the taper.
  • As is explained in detail subsequently, the stent segments 100, 200 and 300 are secured in position by the graft material.
  • The first, second and third stent segments 100, 200, 300 are preferably self-expandable and formed from a shape memory alloy. Such an alloy may be deformed from an original, heat-stable configuration to a second, heat-unstable configuration. The application of a desired temperature causes the alloy to revert to an original heat-stable configuration. A particularly preferred shape memory alloy for this application is binary nickel titanium alloy comprising about 55.8 percent Ni by weight, commercially available under the trade designation NITINOL. This NiTi alloy undergoes a phase transformation at physiological temperatures. A stent made of this material is deformable when chilled. Thus, at low temperatures, for example, below twenty degrees centigrade, the stent is compressed so that it can be delivered to the desired location. The stent may be kept at low temperatures by circulating chilled saline solutions. The stent expands when the chilled saline is removed and it is exposed to higher temperatures within the patient's body, generally around thirty-seven degrees centigrade.
  • In preferred embodiments, each stent is fabricated from a single piece of alloy tubing. The tubing is laser cut, shape-set by placing the tubing on a mandrel, and heat-set to its desired expanded shape and size.
  • In preferred embodiments, the shape setting is performed in stages at five hundred degrees centigrade. That is, the stents are placed on sequentially larger mandrels and briefly heated to five hundred degrees centigrade. To minimize grain growth, the total time of exposure to a temperature of five hundred degrees centigrade is limited to five minutes. The stents are given their final shape set for four minutes at five hundred fifty degrees centigrade, and then aged to a temperature of four hundred seventy degrees centigrade to import the proper martensite to austenite transformation temperature, then blasted, as described in detail subsequently, before electropolishing. This heat treatment process provides for a stent that has a martensite to austenite transformation which occurs over a relatively narrow temperature range; for example, around fifteen degrees centigrade.
  • To improve the mechanical integrity of the stent, the rough edges left by the laser cutting are removed by combination of mechanical grit blasting and electropolishing. The grit blasting is performed to remove the brittle recast layer left by the laser cutting process. This layer is not readily removable by the electropolishing process, and if left intact, could lead to a brittle fracture of the stent struts. A solution of seventy percent methanol and thirty percent nitric acid at a temperature of minus forty degrees centgrade or less has been shown to work effectively as an electropolishing solution. Electrical parameters of the electropolishing are selected to remove approximately 0.00127 cm of material from the surfaces of the struts. The clean, electropolished surface is the final desired surface for attachment to the graft materials. This surface has been found to import good corrosion resistance, fatigue resistance, and wear resistance.
  • The graft material or component 400, as illustrated in Figure 1, may be made from any number of suitable biocompatible materials, including woven, knitted, sutured, extruded, or cast materials comprising polyester, polytetrafluoroethylene, silicones, urethanes, and ultralight weight polyethylene, such as that commercially available under the trade designation SPECTRA. The materials may be porous or nonporous. Exemplary materials include a woven polyester fabric made from DACRON or other suitable PET-type polymers.
  • In one exemplary embodiment, the fabric for the graft material is a forty denier (denier is defined in grams of nine thousand meters of a filament or yarn), twenty-seven filament polyester yarn, having about seventy to one-hundred end yarns per cm per face and thirty-two to forty-six pick yarns per cm face. At this weave density, the graft material is relatively impermeable to blood flow through the wall, but is relatively thin, ranging between 0.08 and 0.12 mm in wall thickness.
  • The graft component 400 is a single lumen tube and preferably has a taper and flared portion woven directly from the loom, as illustrated for the endovascular graft 10 shown in Figure 1.
  • Prior to attachment of the graft component 400 to the stents 100, 200, 300, crimps are formed between the stent positions by placing the graft material on a shaped mandrel and thermally forming indentations in the surface. In the exemplary embodiment illustrated in Figures 1 and 4, the crimps 402 in the graft 400 are about two mm long and 0.5 mm deep. With these dimensions, the endovascular graft 10 can bend and flex while maintaining an open lumen. Also, prior to attachment of the graft component 400 to the stents 100, 200 300, the graft material is cut in a shape to mate with the end of each end stent.
  • As stated above, each of the stent segments 100, 200 and 300 is attached to the graft material 400. The graft material 400 may be attached to the stent segments 100, 200, 300 in any number of suitable ways. In one exemplary embodiment, the graft material 400 may be attached to the stent segments 100, 200, 300 by sutures.
  • The method of suturing stents in place is important for minimizing the relative motion or rubbing between the stent struts and the graft material. Because of the pulsatile motion of the vasculature and therefore the graft system, it is possible for relative motion to occur, particularly in areas where the graft system is in a bend, or if there are residual folds in the graft material, due to being constrained by the aorta or iliac arteries.
  • Ideally, each strut of each stent segment is secured to the graft material by sutures. In an exemplary embodiment, the suture material is blanket stitched to the stent segments at numerous points to securely fasten the graft material to the stent segments. As stated above, a secure hold is desirable in preventing relative motion in an environment in which the graft system experiences dynamic motion arising from pulsatile blood pressure, in addition to pulsation of the arteries that are in direct mechanical contact with the graft system. The stents nearest the aortic and iliac ends of the graft system (the uppermost first stent segment 100 and the third stent segment 300 respectively) are subject to the pulsatile motion arising from direct internal contact. These struts in particular should be well secured to the graft material. As illustrated in Figure 4, the stitches 404 on the upper most first stent segment 100 are positioned along the entire zigzag arrangement of struts. The upper and lower apexes of the third stent segment may be stitched utilizing a similar configuration. It is difficult to manipulate the suture thread precisely around the struts that are located some distance away from an open end, accordingly, various other simpler stitches may be utilized on these struts, or no stitches may be utilized in these areas.
  • As illustrated in Figure 4, each of the struts in the first stent segment 100 is secured to the graft material 400 which has been cut to match the shape of the stent segment 100. The blanket stitching 404 completely encircles the strut and bites into the graft material 400. Preferably, the stitch 404 encircles the strut at approximately five equally spaced locations. Each of the struts on each end of the third stent segment 300 is attached to the graft material, which has been cut to make the shape of the stent segment 300, in the same manner as the first stent segment 100.
  • A significant portion of the graft will not rest directly against vascular tissue. This portion of the graft will be within the dilated aneurysm itself. Therefore, this portion of the graft will not experience any significant pulsatile motion. For this reason, it is not necessary to secure the stent segments to the graft material as aggressively as the stent structure described above. Therefore, only point stitches 406 are necessary for securing these stents.
  • It is important to note that a wide variety of sutures are available. It is equally important to note that there are a number of alternative means for attaching the graft material to the stent, including welding, gluing and chemical bonding.
  • As stated above, In percutaneous procedures, size is a critical factor. One of the more significant determinants of the final diameter of the catheter system is the bulkiness of the graft material comprising the stent-graft. Accordingly, it is generally accepted that the highest impact on delivery catheter diameter may be achieved by fabricating stent-grafts having thinner walls.
  • Typical stent-grafts are fabricated from a woven polyester and are approximately 0.127 mm (0.005 inches) thick. For example, a stent-graft fabricated from a woven polyester low twist, forty denier, twenty-seven filament yarn having two-hundred thirty yarn ends per inch and one hundred yarn picks per inch, results in a graft material having a wall thickness of approximately 0.127 mm (0.005 inches). The graft material is then attached to the inside or outside of a stent or multiple stent segments as described above. Appreciable gains may be achieved in having a graft material thickness in the range from about 0.051 mm (0.002 inches) to about 0.076mm (0.003 inches).
  • For a woven graft, as described above, the wall thickness is determined primarily by weave density and yarn thickness or bulkiness. It is desirable to have a graft which is packed tight enough to prevent significant blood seepage, but not so tight that the yarn bundles pile up on each other. The weaving parameters described above result in just such a graft for the particular yarn described. At this density, the graft material is about as thin walled as it can be without significant permeability. Also, the yarn described above is only lightly twisted, so as the yarn bundles cross over one another, they tend to flatten out. Higher twisting would both make the graft more permeable and thicker, and the yarn bundle would tend to remain cylindrical at the crossover points. The only remaining parameter that can be utilized to thin the graft is smaller yarn bundles.
  • There are two variables which influence yarn bundle size; namely, the number of filaments per bundle, and the size or weight of each individual filament. The forty denier, twenty-seven filament polyester yarn described above has a relatively small filament size and a relatively low number of filaments. However, in theory, a much smaller yarn bundle could be contemplated with either few filaments, smaller filaments, or both. For example, a twenty denier yarn bundle could be made from fourteen filaments of the same diameter as described above. If this yarn were woven into a graft material with an appropriately dense weave, one would expect a graft material having a thickness of approximately 0.063 mm (0.0025 inches). While this may work as an acceptable graft, it is possible that the long-term integrity of such a graft may not be acceptable due to the forces described above.
  • The graft material may be formed utilizing any number of techniques, including weaving, knitting and braiding. Weaving involves the interlacing, at right angles, of two systems of threads known as warp and filling. Warp threads run lengthwise in a woven fabric and filling threads run cross-wise. Knitting is the process of making fabric by interlocking a series of loops of one or more threads. Braiding involves crossing diagonally and lengthwise several threads of any of the major textile fibers to obtain a certain width effect, pattern or style.
  • A growing concern with a number of endovascular graft systems has been that over time, holes may develop in the stent-graft wall, which can lead to blood leakage and possible aneurysm rupture. There is only a limited understanding of the mechanism of hole formation; however, it is generally believed to be related to what has been termed chronic micro-motion between the metallic stent support structures and the graft material. Eventually, this micro-motion may cause the graft material to wear away, thereby creating holes.
  • One potential way in which to overcome this problem is by more tightly binding the graft material to the stent in areas exhibiting the highest possibility of micro-motion. There are numerous ways by which the graft material may be attached to the stent, for example, polymeric sutures. Accordingly, it may be possible to simply create a thinner polyester graft material as described above, more tightly secure it to the stent in areas which exhibit the greatest potential for micro-motion, and have a lower profile, longer wear resistant stent-graft. However, it would also be beneficial to consider alternate materials for fabricating a significantly thinner graft material with high wear resistance. Higher strength and/or tougher materials may yield a much thinner stent-graft conduit without sacrificing long-term integrity. In fact, some of the materials that may be utilized are so much stronger and tougher than polyester sold under the mark Dacron, that a significantly thinner stent-graft constructed of these materials may be substantially stronger and more wear resistant than currently available stent-grafts.
  • There are a number of new, higher performance fibers that are significantly stronger and tougher than polyester, and which are also biocompatible. Whereas, polyester sold under the mark Dacron has a tenacity of approximately nine grams per denier, many high performance fibers have tenacities in the range from about thirty-five to about forty-five grams per denier. The more preferred fibers from a strength standpoint for consideration for use in an ultra thin walled stent-graft material, approximately, 0.051 to 0.076 mm (0.002 to 0.003 inches) include polyaramid, polyphynelenebenzobisoxazole, liquid crystal polymer and ultra high molecular weight polyethylene. From a purely strength standpoint, all of these materials are suitable for ultra-thin walled stent-graft applications. However, from a biostability standpoint, ultra high molecular weight polyethylene fibers may offer a slight advantage in the fact that their basic chemistry is polyethylene, which is known to be relatively inert in biological applications.
  • Another important consideration for the above-described fibers is their availability in fine denier yarns. With current stent-grafts fabricated from a forty denier polymer yarn, it would be difficult to fabricate a stent-graft having thinner walls unless the yarn is of a finer denier. A liquid crystal polymer sold under the tradename Vectran is available as a twenty-five denier yarn. A ultra high molecular weight polyethylene sold under the tradename Spectra is available as a thirty-denier yarn. Another ultra high molecular weight polyethylene sold under the tradename Dyneema is available as a twenty to twenty-five denier yarn. It is also important to consider that ultra high molecular weight polyethylene fibers only have a density of 0.97 versus 1.38, so that the same denier yarn would be bulkier in ultra high molecular weight polyethylene, however, due to the substantial improvement in tensile and abrasive properties, much less ultra high molecular weight polyethylene would be necessary to obtain equivalent material properties.
  • Polyethylene is a long chain organic polymer formed by the polymerization of ethylene. When formed under low pressure, it will form long polymer chains which increases its resistance to fracture. Ultra high molecular weight polyethylene typically has between six and twelve million ethylene units per molecule. Ultra high molecular weight polyethylene has a low coefficient of friction, a high molecular weight and a high density. Accordingly, a fabric made from ultra high molecular weight polyethylene is highly abrasion resistant, highly impact resistant, and highly resistant to damage by water, salt or fresh. Ultra high molecular weight polyethylene monofilaments have a high tensile strength with the associated advantage of stretch resistance and elasticity. These properties make it especially suitable for tortuous body passageways.
  • As stated above, polyethylene has a long documented history of biocompatability. Given this level of biocompatability, coupled with its physical attributes, ultra high molecular weight polyethylene is the preferred yarn for use as a graft material. The ultra high molecular weight polyethylene yarn may be woven, knitted or braided to form the graft material and attached to the one or more stent segments as described above. The graft material may also be used as a strand alone device for surgical applications or combined with the one or more stents for endovascular delivery.
  • In alternate exemplary embodiments, the ultra high molecular weight polyethylene yarn may be blended with a dissimilar material, for example, Dacron® polyester, to manufacture a graft material with altered bulk properties; e.g., stretch potential, while retaining strength and abrasion resistance. In yet other alternate exemplary embodiment, the monofilament of ultra high molecular weight polyethylene may be blended together with another material to attain a true blended yarn such that a fiber or monofilament of one material can be placed next to a monofilament of a second material (third, fourth...) to create a resultant yarn which possesses properties that differ from each of its monofilaments.
  • As described above, graft material may be attached to stents or stent segments in any number of suitable ways. In one exemplary embodiment, the graft material may be attached by suturing the graft material to the stent lattice at predetermined locations as described herein. In an alternate exemplary embodiment, the graft material may be attached to the stent or stent segments via an attachment device that holds or sandwiches the graft material between itself and a portion of the stent. In this approach, the graft material is not punctured. The attachment device may comprise any suitable configuration such as a band or clip and may be formed from any suitable material. It is important to note that the attachment device may be utilized for applications other than the attachment of graft material to stents or stent segments. For example, the attachment device may be utilized to attach or secure any substantially flexible material or covering to another element or substrate.
  • Referring to Figures 5a-5d, there is illustrated an exemplary attachment device 500 in accordance with the present invention. Figures 5a-5d illustrate a progression of cross-sectional views of the attachment device 500, a segment of a stent 502, and a segment of graft material 504 as the attachment device 500 is positioned and secured into place. As illustrated in Figure 5a, the attachment device 500 is positioned over the graft material 504 and a segment of a stent 502. The attachment device 500 may comprise any suitable shape, size and material. Preferably, the attachment device 500 comprises a shape and material that allows it to be positioned over the graft material 504 and stent segment 502 and then crimped or otherwise manipulated into a configuration such that it substantially conforms to the shape of the stent segment 502 as illustrated in Figure 5d. With this snug fit, the overall profile of the stent-graft or other device will not be significantly impacted or affected. In addition, the attachment device 500 preferably comprises a material that exhibits minimal fatigue wear when undergoing the crimping process.
  • In the exemplary embodiment, the attachment device 500 comprises a simple band, clip or ring structure formed by creating a longitudinal slit or opening in a tubular structure. The slit or opening may be formed by any suitable machining technique. The attachment device 500, as stated above, may be formed from any suitable material, including plastics and metals. For example, the attachment device may comprise polymeric materials or various metallic materials such as stainless steel or tantalum. Depending on the material utilized for the stent, it may be desirable to utilize a highly radiopaque material for the attachment device 500 so that it may serve the dual purpose of securing the graft material to the stent and act as a marker band for properly deploying the stent-graft in position. Metallic materials such as tantalum are highly radiopaque. If the stent is formed from a highly radiopaque material or utilizes other marker elements, then any other suitable material may be utilized for the attachment device 500.
  • In alternate exemplary embodiments, the attachment device 500 may be formed by mechanical shape setting of a thermal or shape memory material or by ultrasonic welding.
  • Once the attachment device 500 is positioned around the stent segment 502 with the graft material 504 sandwiched therebetween, it may be crimped snuggly around the stent segment 502 as illustrated in the progression of Figures 5a through 5d. As illustrated in Figure 5d, the attachment device 500 securely holds the graft material 504 to the stent segment 502 without creating any openings in the graft material 504. The attachment device 500 may be utilized anywhere the sutures described above may be utilized. In addition, if the attachment devices 500 are utilized as markers, the shape and/or size of the attachment devices 500 may vary depending on their location on the stent or stent segment so that exact positioning may be achieved.
  • As described above, by conforming the attachment device 500 to the stent 502, the graft material 504 may be securely held in position and the overall profile of the stent-graft will not be significantly impacted. In order to further minimize the impact on the profile of the stent-graft, the thickness of the attachment device 500 may be maintained to less than that of the suture/suture knot.
  • In an alternate exemplary embodiment, the attachment device 500 and/or the stent segment 502 may be modified such that the attachment device 500 slips or gives as the stent moves. For example, some or all of the attachment devices 500 may be fixed in position by complete crimping or some or all of the attachment devices 500 may be slidably mounted to accommodate stent lengthening during crimping. The attachment devices 500 may be slidably mounted by less than complete crimping, by designing the attachment devices 500 to allow movement even when fully crimped or by modifying some or all of the stent segments. For example, referring to Figure 6, there is illustrated a stent segment 602 having a reduced profile section 604 that would allow the attachment device 500 to move in that area, but not beyond the area.
  • As described above, in one exemplary embodiment, the attachment device 500 comprises a simple band, clip or ring structure formed from a tube with a longitudinal slit. The slit is expanded to fit over the stent element, for example, the stent struts, and graft material, and then crimped, squeezed or deformed to wrap around the strut and graft material. The attachment device 500 may also be made of a tubular structure that is bent or deformed into a substantially kidney shape, then placed and crimped. This design would preferably minimize and damage caused by any potential sharp edges formed during crimping. Similar shapes such as a disc could be used and formed to wrap around the stent segment and graft material.
  • The attachment device 500, as illustrated in Figures 5a-5d may be utilized for attaching an implantable graft material to a stent such as used in the fabrication of a covered stent, stent-graft, endoleg or any other device that requires a covering to be attached to a substrate. As described above, in one exemplary embodiment, the attachment device 500 comprises a hypotube segment that has a slit or slice cut longitudinally such that as to create an opening for accepting the stent and graft fabric. The attachment device 500 is fitted onto the stent strut 502 and graft material 504 by slipping the stent 502 and graft material 504 through the slit as illustrated in Figure 5a. Then the attachment device 500 is crimped to capture or hold the stent 502 and graft material 504 together as illustrated in Figure 5d.
  • Figures 7a-c illustrate an exemplary crimping tool 700 that may be utilized to squeeze or crimp the attachment device 500 and deform it into its final shape. As illustrated, the crimping tool 700 comprises a pair of pivotally moveable jaws 702,704. In operation, the jaws 702,704 are opened a distance sufficient to fit around the attachment device 500, the stent strut 502 and the graft material 504 as illustrated in Figure 7a. Once positioned properly, the jaws 702,704 are pivoted together, as illustrated in Figure 7b, until the attachment device 500 fits snuggly around the stent strut 502 and graft material 504, as illustrated in Figure 7c.
  • The jaws 702,704 of the crimping tool 700 may comprise any suitable configuration and may be formed from any suitable material. The crimping tool 700 is preferably configured like pliers with jaws 702,704 being configured to the shape of stent struts. Accordingly, different crimping tools 700 may be employed with stents having different struts shapes. Preferably, the crimping tool 700 may be configured such that the jaws 702,704 are interchangeable or that they may be fitted with inserts that conform to the shape of the particular strut. In addition, the crimping tool 700 may comprise a means for limiting the pressure applied to the struts and graft material. For example, the crimping tool 700 may comprise a mechanical stop that limits the composition of the jaws 702,704 or an adjustable stop similar to mechanism utilized in vise grips.
  • It is important to note that the attachment device of the present invention may be utilized to attach graft material or graft like material to any number of medical devices. The above-described stents and graft material (Figures 1-4) are for illustrative purposes and not intended to limit the scope of the claimed invention. In other words, the attachment device of the present invention may be utilized with any stent and with any graft material, or as stated above, the attachment device may be utilized to attach or secure any substantially flexible material or covering to another element or substrate.
  • The attachment device of the present invention offers a number of substantial advantages over existing attachment technology. The attachment device would be insulated from the stent framework by a layer of graft material which in turn reduces or substantially eliminates bimetallic coupling thus reducing or substantially eliminating the risk of galvanic corrosion. The attachment device does not require a breach of the graft material to secure the graft to the stent. This eliminates the suture or staple holes that are created with attachments of other designs and greatly reduces the chance of leaking through at the attachment sites. No portion of the attachment device needs to be placed interior of the graft material and therefore if an attachment device failed in a long term situation it would be captured or trapped between the outside of the stent graft and the vessel wall minimizing the chance of particle emboli. The manufacture of a stent graft utilizing the attachment device of the present invention is greatly simplified since all assembly work may be done from the exterior of the stent. The attachment device of the present invention is a low profile device and may serve a dual role as a connection means and radiopaque marker.
  • It is important to note that the attachment device 500 of the present invention may be utilized alone or in combination with other attachment means including sutures and/or staples as described above.

Claims (20)

  1. An attachment device comprising a deformable, partially tubular band having a slotted opening for accepting a portion of a first substantially flexible element and a portion of a second substrate element.
  2. The attachment device according to Claim 1, wherein the partially tubular band comprises a polymeric material.
  3. The attachment device according to Claim 1, wherein the partially tubular band comprises a metallic material.
  4. The attachment device according to Claim 1, wherein the partially tubular band is configured to hold a portion of the first substantially flexible element between itself and a portion of the second substrate element.
  5. A stent graft comprising:
    one or more stent structures;
    a biocompatible graft material affixed to the one or more stent structures; and
    at least one attachment device for securing the biocompatible graft material to the one or more stent structures, the at least one attachment device comprising a deformable, partially tubular band having a slotted opening for accepting a portion of the one or more stent structures and a portion of the biocompatible graft material.
  6. The stent graft according to Claim 5, wherein the graft material comprises ultra high molecular weight polyethylene.
  7. The stent graft according to Claim 5, wherein the graft material comprises polyaramid.
  8. The stent graft according to Claim 5, wherein the graft material comprises polyphynelenebenzobisoxazole.
  9. The stent graft according to Claim 5, wherein the graft material comprises liquid crystal polymer.
  10. The stent graft according to Claim 6, wherein the ultra high molecular weight polyethylene graft material comprises a yarn having a weight in the range from about twenty denier to about thirty denier.
  11. The stent graft according to Claim 5, wherein the graft material comprises blends of ultra high molecular weight polyethylene.
  12. The stent graft according to Claim 5, wherein the graft material is woven.
  13. The stent graft according to Claim 5, wherein the graft material is knitted.
  14. The stent graft according to Claim 5, wherein the graft material is braided.
  15. The stent graft according to Claim 5, wherein the at least one attachment device comprises a polymeric material.
  16. The stent graft according to Claim 5, wherein the at least one attachment device comprises a metallic material.
  17. The stent graft according to Claim 5, wherein the partially tubular band is configured to hold a portion of the biocompatible graft material between itself and a portion of the one or more stent structures.
  18. The stent graft according to Claim 17, wherein the partially tubular band is configured to allow relative movement between the portion of the biocompatible graft material and the portion of the one or more stent structures.
  19. The stent graft according to Claim 17, wherein the portion of the stent structure is configured to allow relative movement between the portion of the biocompatible graft material and the portion of the one or more stent structures.
  20. A method for attaching graft material to a stent structure comprising:
    positioning graft material around a stent structure;
    positioning at least one attachment device such that the graft material is sandwiched between the at least one attachment device and a portion of the stent structure, and
    crimping the at least one attachment device around the graft material at the portion of the stent structure.
EP04256158A 2003-10-07 2004-10-05 Stent-Graft with slidably mounted graft material and method of attachment Active EP1522277B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US680805 2003-10-07
US10/680,805 US8088156B2 (en) 2003-10-07 2003-10-07 Graft material attachment device and method

Publications (3)

Publication Number Publication Date
EP1522277A2 true EP1522277A2 (en) 2005-04-13
EP1522277A3 EP1522277A3 (en) 2005-06-08
EP1522277B1 EP1522277B1 (en) 2008-10-15

Family

ID=34314112

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04256158A Active EP1522277B1 (en) 2003-10-07 2004-10-05 Stent-Graft with slidably mounted graft material and method of attachment

Country Status (6)

Country Link
US (1) US8088156B2 (en)
EP (1) EP1522277B1 (en)
JP (1) JP4864309B2 (en)
AT (1) ATE410978T1 (en)
CA (1) CA2484252C (en)
DE (1) DE602004017101D1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1986573A2 (en) * 2006-02-03 2008-11-05 Bolton Medical Inc. Delivery system and meth0d for self-centering a proximal end of a stent graft
WO2013087898A1 (en) 2011-12-14 2013-06-20 Dsm Ip Assets B.V. Process for medical components and uses thereof
EP2608731A1 (en) * 2010-08-27 2013-07-03 ECP Entwicklungsgesellschaft mbH Implantable blood conveying device, manipulating device and coupling device
US8636788B2 (en) 2003-09-03 2014-01-28 Bolton Medical, Inc. Methods of implanting a prosthesis
US8998970B2 (en) 2012-04-12 2015-04-07 Bolton Medical, Inc. Vascular prosthetic delivery device and method of use
US9101506B2 (en) 2009-03-13 2015-08-11 Bolton Medical, Inc. System and method for deploying an endoluminal prosthesis at a surgical site
US9173755B2 (en) 2003-09-03 2015-11-03 Bolton Medical, Inc. Vascular repair devices
US9220617B2 (en) 2003-09-03 2015-12-29 Bolton Medical, Inc. Dual capture device for stent graft delivery system and method for capturing a stent graft
US9333104B2 (en) 2003-09-03 2016-05-10 Bolton Medical, Inc. Delivery systems for delivering and deploying stent grafts
US9364314B2 (en) 2008-06-30 2016-06-14 Bolton Medical, Inc. Abdominal aortic aneurysms: systems and methods of use
US9439751B2 (en) 2013-03-15 2016-09-13 Bolton Medical, Inc. Hemostasis valve and delivery systems
US9877857B2 (en) 2003-09-03 2018-01-30 Bolton Medical, Inc. Sheath capture device for stent graft delivery system and method for operating same
US11259945B2 (en) 2003-09-03 2022-03-01 Bolton Medical, Inc. Dual capture device for stent graft delivery system and method for capturing a stent graft
US11596537B2 (en) 2003-09-03 2023-03-07 Bolton Medical, Inc. Delivery system and method for self-centering a proximal end of a stent graft

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949121B1 (en) * 2002-02-07 2005-09-27 Sentient Engineering & Technology, Llc Apparatus and methods for conduits and materials
US8425549B2 (en) 2002-07-23 2013-04-23 Reverse Medical Corporation Systems and methods for removing obstructive matter from body lumens and treating vascular defects
DE102005016103B4 (en) * 2005-04-08 2014-10-09 Merit Medical Systems, Inc. Duodenumstent
DE102005019649A1 (en) * 2005-04-26 2006-11-02 Alveolus Inc. Flexible stent for positioning in lumen of esophagus comprises tube and stabilization members defined circumferentially about tube, where each member extends inwardly in tube to define inner diameter that is less than inner diameter of tube
US8425584B2 (en) 2006-04-21 2013-04-23 W. L. Gore & Associates, Inc. Expandable covered stent with wide range of wrinkle-free deployed diameters
US8721704B2 (en) * 2006-04-21 2014-05-13 W. L. Gore & Associates, Inc. Expandable stent with wrinkle-free elastomeric cover
US8663309B2 (en) * 2007-09-26 2014-03-04 Trivascular, Inc. Asymmetric stent apparatus and method
US8226701B2 (en) 2007-09-26 2012-07-24 Trivascular, Inc. Stent and delivery system for deployment thereof
US20090082847A1 (en) * 2007-09-26 2009-03-26 Boston Scientific Corporation System and method of securing stent barbs
US8066755B2 (en) 2007-09-26 2011-11-29 Trivascular, Inc. System and method of pivoted stent deployment
CN101917929A (en) 2007-10-04 2010-12-15 特里瓦斯库拉尔公司 Modular vascular graft for low profile percutaneous delivery
US8088140B2 (en) 2008-05-19 2012-01-03 Mindframe, Inc. Blood flow restorative and embolus removal methods
US8066757B2 (en) 2007-10-17 2011-11-29 Mindframe, Inc. Blood flow restoration and thrombus management methods
US9198687B2 (en) 2007-10-17 2015-12-01 Covidien Lp Acute stroke revascularization/recanalization systems processes and products thereby
US9220522B2 (en) 2007-10-17 2015-12-29 Covidien Lp Embolus removal systems with baskets
US8585713B2 (en) 2007-10-17 2013-11-19 Covidien Lp Expandable tip assembly for thrombus management
US10123803B2 (en) 2007-10-17 2018-11-13 Covidien Lp Methods of managing neurovascular obstructions
US8926680B2 (en) 2007-11-12 2015-01-06 Covidien Lp Aneurysm neck bridging processes with revascularization systems methods and products thereby
US11337714B2 (en) 2007-10-17 2022-05-24 Covidien Lp Restoring blood flow and clot removal during acute ischemic stroke
US8083789B2 (en) 2007-11-16 2011-12-27 Trivascular, Inc. Securement assembly and method for expandable endovascular device
US8328861B2 (en) * 2007-11-16 2012-12-11 Trivascular, Inc. Delivery system and method for bifurcated graft
KR101819554B1 (en) 2008-02-22 2018-01-17 마이크로 테라퓨틱스 인코포레이티드 Methods and apparatus for flow restoration
CN101977650A (en) 2008-04-11 2011-02-16 曼德弗雷姆公司 Monorail neuro-microcatheter for delivery of medical devices to treat stroke, processes and products thereby
US8394138B2 (en) * 2008-09-05 2013-03-12 Cook Medical Technologies Llc Multi-strand helical stent
US8641753B2 (en) 2009-01-31 2014-02-04 Cook Medical Technologies Llc Preform for and an endoluminal prosthesis
AU2010207983B2 (en) * 2009-02-02 2015-05-14 Cardinal Health 529, Llc Flexible stent design
CN102811672A (en) * 2009-11-03 2012-12-05 大口径封闭有限责任公司 Closure Device
EP2519189B1 (en) 2009-12-28 2014-05-07 Cook Medical Technologies LLC Endoluminal device with kink-resistant regions
AU2012203620B9 (en) 2011-06-24 2014-10-02 Cook Medical Technologies Llc Helical Stent
US8992595B2 (en) 2012-04-04 2015-03-31 Trivascular, Inc. Durable stent graft with tapered struts and stable delivery methods and devices
US9498363B2 (en) 2012-04-06 2016-11-22 Trivascular, Inc. Delivery catheter for endovascular device
US20140067000A1 (en) * 2012-09-06 2014-03-06 Ticona Llc Implantable Medical Device Containing Fibers Formed from a Liquid Crystalline Polymer
EP3585312A4 (en) * 2017-02-27 2020-12-02 Dura LLC Novel transcatheter valve replacement device
EP3698756A4 (en) * 2017-10-16 2021-08-04 Kawasumi Laboratories, Inc. Stent graft
JP2022525788A (en) 2019-03-20 2022-05-19 インキュベート メディカル テクノロジーズ、 エルエルシー Aortic dissection implant

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020002397A1 (en) * 1995-12-14 2002-01-03 Martin Gerald Ray Kink resistant stent-graft
US6342059B1 (en) * 1997-12-16 2002-01-29 B. Braun Celsa Medical treatment of an affection of an anatomical duct
US6482227B1 (en) * 1998-03-30 2002-11-19 Cordis Corporation Stent graft having improved attachment within a body vessel

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53131357A (en) 1977-04-25 1978-11-16 Konchinen Maruchi Method of and device for folding and sealing film
JP3165166B2 (en) * 1991-02-27 2001-05-14 セーレン株式会社 Artificial blood vessel and method for producing the same
CA2149900C (en) * 1993-09-24 2003-06-24 Yasuo Shikinami Implant material
US5527355A (en) * 1994-09-02 1996-06-18 Ahn; Sam S. Apparatus and method for performing aneurysm repair
US6551350B1 (en) * 1996-12-23 2003-04-22 Gore Enterprise Holdings, Inc. Kink resistant bifurcated prosthesis
US6511506B2 (en) * 1997-10-01 2003-01-28 B. Braun Celsa Medical set for intervention on an anatomical duct, sealing ring pertaining to said set and use of said ring
US6132457A (en) * 1997-10-22 2000-10-17 Triad Vascular Systems, Inc. Endovascular graft having longitudinally displaceable sections
WO1999049927A1 (en) * 1998-03-27 1999-10-07 Kanji Inoue Transplantation device
JP4889151B2 (en) * 1998-09-08 2012-03-07 株式会社 京都医療設計 Vascular stent
GB2347861B (en) * 1999-03-13 2003-11-26 Biointeractions Ltd Biocompatible endoprostheses
US6929658B1 (en) 2000-03-09 2005-08-16 Design & Performance-Cyprus Limited Stent with cover connectors
ATE331487T1 (en) * 2000-03-09 2006-07-15 Design & Performance Cyprus Lt STENT WITH SHEATH ATTACHMENTS
AU780393B2 (en) * 2000-11-16 2005-03-17 Cordis Corporation An improved stent for use in a stent graft
AUPR847301A0 (en) * 2001-10-26 2001-11-15 Cook Incorporated Endoluminal prostheses for curved lumens
WO2004016199A1 (en) * 2002-08-15 2004-02-26 Gmp Cardiac Care, Inc. Stent-graft with rails

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020002397A1 (en) * 1995-12-14 2002-01-03 Martin Gerald Ray Kink resistant stent-graft
US6342059B1 (en) * 1997-12-16 2002-01-29 B. Braun Celsa Medical treatment of an affection of an anatomical duct
US6482227B1 (en) * 1998-03-30 2002-11-19 Cordis Corporation Stent graft having improved attachment within a body vessel

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9913743B2 (en) 2003-09-03 2018-03-13 Bolton Medical, Inc. Methods of implanting a prosthesis and treating an aneurysm
US9561124B2 (en) 2003-09-03 2017-02-07 Bolton Medical, Inc. Methods of self-aligning stent grafts
US11813158B2 (en) 2003-09-03 2023-11-14 Bolton Medical, Inc. Stent graft delivery device
US9925080B2 (en) 2003-09-03 2018-03-27 Bolton Medical, Inc. Methods of implanting a prosthesis
US8636788B2 (en) 2003-09-03 2014-01-28 Bolton Medical, Inc. Methods of implanting a prosthesis
US8740963B2 (en) 2003-09-03 2014-06-03 Bolton Medical, Inc. Methods of implanting a prosthesis and treating an aneurysm
US11596537B2 (en) 2003-09-03 2023-03-07 Bolton Medical, Inc. Delivery system and method for self-centering a proximal end of a stent graft
US11413173B2 (en) 2003-09-03 2022-08-16 Bolton Medical, Inc. Stent graft with a longitudinal support member
US9173755B2 (en) 2003-09-03 2015-11-03 Bolton Medical, Inc. Vascular repair devices
US9220617B2 (en) 2003-09-03 2015-12-29 Bolton Medical, Inc. Dual capture device for stent graft delivery system and method for capturing a stent graft
US9320631B2 (en) 2003-09-03 2016-04-26 Bolton Medical, Inc. Aligning device for stent graft delivery system
US9333104B2 (en) 2003-09-03 2016-05-10 Bolton Medical, Inc. Delivery systems for delivering and deploying stent grafts
US10646365B2 (en) 2003-09-03 2020-05-12 Bolton Medical, Inc. Delivery system and method for self-centering a proximal end of a stent graft
US9408735B2 (en) 2003-09-03 2016-08-09 Bolton Medical, Inc. Methods of implanting a prosthesis and treating an aneurysm
US9408734B2 (en) 2003-09-03 2016-08-09 Bolton Medical, Inc. Methods of implanting a prosthesis
US10390929B2 (en) 2003-09-03 2019-08-27 Bolton Medical, Inc. Methods of self-aligning stent grafts
US10918509B2 (en) 2003-09-03 2021-02-16 Bolton Medical, Inc. Aligning device for stent graft delivery system
US10213291B2 (en) 2003-09-03 2019-02-26 Bolto Medical, Inc. Vascular repair devices
US9655712B2 (en) 2003-09-03 2017-05-23 Bolton Medical, Inc. Vascular repair devices
US11259945B2 (en) 2003-09-03 2022-03-01 Bolton Medical, Inc. Dual capture device for stent graft delivery system and method for capturing a stent graft
US9877857B2 (en) 2003-09-03 2018-01-30 Bolton Medical, Inc. Sheath capture device for stent graft delivery system and method for operating same
US9907686B2 (en) 2003-09-03 2018-03-06 Bolton Medical, Inc. System for implanting a prosthesis
US10182930B2 (en) 2003-09-03 2019-01-22 Bolton Medical, Inc. Aligning device for stent graft delivery system
US11103341B2 (en) 2003-09-03 2021-08-31 Bolton Medical, Inc. Stent graft delivery device
US10945827B2 (en) 2003-09-03 2021-03-16 Bolton Medical, Inc. Vascular repair devices
US10105250B2 (en) 2003-09-03 2018-10-23 Bolton Medical, Inc. Dual capture device for stent graft delivery system and method for capturing a stent graft
EP1986573A2 (en) * 2006-02-03 2008-11-05 Bolton Medical Inc. Delivery system and meth0d for self-centering a proximal end of a stent graft
EP1986573A4 (en) * 2006-02-03 2013-04-10 Bolton Medical Inc Delivery system and meth0d for self-centering a proximal end of a stent graft
US10105248B2 (en) 2008-06-30 2018-10-23 Bolton Medical, Inc. Abdominal aortic aneurysms: systems and methods of use
US10864097B2 (en) 2008-06-30 2020-12-15 Bolton Medical, Inc. Abdominal aortic aneurysms: systems and methods of use
US10307275B2 (en) 2008-06-30 2019-06-04 Bolton Medical, Inc. Abdominal aortic aneurysms: systems and methods of use
US11382779B2 (en) 2008-06-30 2022-07-12 Bolton Medical, Inc. Abdominal aortic aneurysms: systems and methods of use
US9364314B2 (en) 2008-06-30 2016-06-14 Bolton Medical, Inc. Abdominal aortic aneurysms: systems and methods of use
US10898357B2 (en) 2009-03-13 2021-01-26 Bolton Medical, Inc. System for deploying an endoluminal prosthesis at a surgical site
US9827123B2 (en) 2009-03-13 2017-11-28 Bolton Medical, Inc. System for deploying an endoluminal prosthesis at a surgical site
US9101506B2 (en) 2009-03-13 2015-08-11 Bolton Medical, Inc. System and method for deploying an endoluminal prosthesis at a surgical site
EP2608731B1 (en) * 2010-08-27 2021-07-21 Berlin Heart GmbH Implantable blood conveying device, manipulating device and coupling device
EP2608731A1 (en) * 2010-08-27 2013-07-03 ECP Entwicklungsgesellschaft mbH Implantable blood conveying device, manipulating device and coupling device
WO2013087898A1 (en) 2011-12-14 2013-06-20 Dsm Ip Assets B.V. Process for medical components and uses thereof
US10299951B2 (en) 2012-04-12 2019-05-28 Bolton Medical, Inc. Vascular prosthetic delivery device and method of use
US9554929B2 (en) 2012-04-12 2017-01-31 Bolton Medical, Inc. Vascular prosthetic delivery device and method of use
US11351049B2 (en) 2012-04-12 2022-06-07 Bolton Medical, Inc. Vascular prosthetic delivery device and method of use
US8998970B2 (en) 2012-04-12 2015-04-07 Bolton Medical, Inc. Vascular prosthetic delivery device and method of use
US10555826B2 (en) 2013-03-15 2020-02-11 Bolton Medical, Inc. Hemostasis valve and delivery systems
US11666467B2 (en) 2013-03-15 2023-06-06 Bolton Medical, Inc. Hemostasis valve and delivery systems
US9439751B2 (en) 2013-03-15 2016-09-13 Bolton Medical, Inc. Hemostasis valve and delivery systems

Also Published As

Publication number Publication date
DE602004017101D1 (en) 2008-11-27
US20050075715A1 (en) 2005-04-07
JP4864309B2 (en) 2012-02-01
CA2484252A1 (en) 2005-04-07
CA2484252C (en) 2009-12-29
JP2005111270A (en) 2005-04-28
EP1522277B1 (en) 2008-10-15
ATE410978T1 (en) 2008-10-15
US8088156B2 (en) 2012-01-03
EP1522277A3 (en) 2005-06-08

Similar Documents

Publication Publication Date Title
US8088156B2 (en) Graft material attachment device and method
EP1386590B1 (en) Abrasion resistant vascular graft
EP1878392B1 (en) AAA repair device with aneurysm sac access port
EP2301476B1 (en) Stent-graft suture locks
US7655037B2 (en) Combination barb restraint and stent attachment deployment mechanism
US20140005764A1 (en) Sealing mechanism for expandable vascular device
EP2548532B1 (en) Stent-graft or graft with durability or stiffness enhancing elements
CA2944014C (en) Method and device for attaching a stent structure to aaa graft material
EP1523999A1 (en) High strength and lubricious materials using spider silk for vascular grafts

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

17P Request for examination filed

Effective date: 20050816

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20061110

17Q First examination report despatched

Effective date: 20061110

RTI1 Title (correction)

Free format text: STENT-GRAFT WITH SLIDABLY MOUNTED GRAFT MATERIAL AND METHOD OF ATTACHMENT

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. AG PATENT- UND MARKENANWAELTE VSP

Ref country code: CH

Ref legal event code: EP

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602004017101

Country of ref document: DE

Date of ref document: 20081127

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090126

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090115

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081015

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081015

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090316

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081015

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081015

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081015

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081015

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081015

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081015

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090115

26N No opposition filed

Effective date: 20090716

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081015

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090416

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081015

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081015

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20180614 AND 20180620

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: SERVOPATENT GMBH, CH

Ref country code: CH

Ref legal event code: PUE

Owner name: CARDINAL HEALTH SWITZERLAND 515 GMBH, CH

Free format text: FORMER OWNER: CORDIS CORPORATION, US

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: WANNERSTRASSE 9/1, 8045 ZUERICH (CH)

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004017101

Country of ref document: DE

Representative=s name: PROCK, THOMAS, DR., GB

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: CARDINAL HEALTH SWITZERLAND 515 GMBH; CH

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT

Effective date: 20200708

REG Reference to a national code

Ref country code: BE

Ref legal event code: PD

Owner name: CARDINAL HEALTH SWITZERLAND 515 GMBH; CH

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), AUTRE, CHANGEMENT D'ADRESSE.

Effective date: 20200416

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20201126 AND 20201202

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004017101

Country of ref document: DE

Representative=s name: PROCK, THOMAS, DR., GB

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004017101

Country of ref document: DE

Owner name: CARDINAL HEALTH SWITZERLAND 515 GMBH, CH

Free format text: FORMER OWNER: CORDIS CORP., MIAMI LAKES, FLA., US

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20211026

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20211027

Year of fee payment: 18

Ref country code: GB

Payment date: 20211027

Year of fee payment: 18

Ref country code: DE

Payment date: 20211027

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20211021

Year of fee payment: 18

Ref country code: FR

Payment date: 20211025

Year of fee payment: 18

Ref country code: CH

Payment date: 20211103

Year of fee payment: 18

Ref country code: BE

Payment date: 20211027

Year of fee payment: 18

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602004017101

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20221101

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20221031

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20221005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221101

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230503

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221005

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221005